var title_f33_32_34304="Pertussis infant";
var content_f33_32_34304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/80861/Pertussis_infant_edt_conv.mp4?title=Pertussis+infant\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classic pertussis cough in an infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sheldon L Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34304=[""].join("\n");
var outline_f33_32_34304=null;
var title_f33_32_34305="Blueberry muffin lesions";
var content_f33_32_34305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blueberry muffin lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This infant with congenital rubella syndrome presented with \"blueberry muffin\" skin lesions. These lesions indicate cutaneous hematopoiesis and may occur in other intrauterine infections and hematologic disorders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Centers for Disease Control and Prevention Public Health Image Library.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34305=[""].join("\n");
var outline_f33_32_34305=null;
var title_f33_32_34306="Terminal ileum endoscopy";
var content_f33_32_34306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Terminal ileum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Terminal ileum seen during colonoscopy. Numerous villi can be seen covering the surface of the terminal ileum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34306=[""].join("\n");
var outline_f33_32_34306=null;
var title_f33_32_34307="Icatibant: Patient drug information";
var content_f33_32_34307=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Icatibant: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     see \"Icatibant: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13206139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Firazyr&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13206032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling of the face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13206020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3517426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to icatibant or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13206022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13206035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13206024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3517505",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is used for swelling in your neck or throat, go to the ER right away after using it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13206034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2996921",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3517428",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use more than 3 doses in a 24 hour period.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13206036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699159",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use if solution changes color.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13206025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16809 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34307=[""].join("\n");
var outline_f33_32_34307=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206139\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206032\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206020\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206022\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206035\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206024\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206034\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206036\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13206025\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=related_link\">",
"      Icatibant: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_32_34308="Light and skin interaction in laser therapy";
var content_f33_32_34308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Interaction between light and skin during laser therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light that reaches the skin surface can be reflected away from the skin, absorbed by light absorbing molecules (chromophores) within the skin, scattered in various directions within the skin, or transmitted through the skin to underlying tissues.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34308=[""].join("\n");
var outline_f33_32_34308=null;
var title_f33_32_34309="Gram stain sputum 7A answer";
var content_f33_32_34309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62782%7EID%2F75468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62782%7EID%2F75468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neisseria meningitidis in sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows inflammatory cells and gram-negative diplococci. Neisseria meningitidis, which is oxidase-positive, grew from this patient's sputum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Test for oxidase activity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On chocolate agar, Neisseria meningitidis forms moderate-sized, translucent colonies which turn black (positive) when a drop of oxidase reagent is added.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34309=[""].join("\n");
var outline_f33_32_34309=null;
var title_f33_32_34310="Necrolytic migratory erythema perineum";
var content_f33_32_34310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Necrolytic migratory erythema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 519px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous patches and erosions with peripheral crusts are present in this patient with necrolytic migratory erythema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34310=[""].join("\n");
var outline_f33_32_34310=null;
var title_f33_32_34311="Evaluation of abnormal behavior in the emergency department";
var content_f33_32_34311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of abnormal behavior in the emergency department",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/32/34311/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/32/34311/contributors\">",
"     J Stephen Huff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/32/34311/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/32/34311/contributors\">",
"     Robert S Hockberger, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/32/34311/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/32/34311/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/32/34311/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered behavior ranges from subjective difficulty thinking clearly to abnormal thought content and states of depressed consciousness. When altered behavior directs the diagnostic workup, this implies that confusion, thought problems, or altered mental status is the chief complaint. Adjunctive complaints such as dyspnea, hypoxia, high fever, or acute focal neurologic deficits shift the clinician's approach.",
"   </p>",
"   <p>",
"    Confusion is thought to be present in up to 50 percent of elderly hospitalized patients, 10 percent of all hospitalized patients, and 2 percent of emergency department patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differentiation of abnormal behavior may be straightforward or complex. Sometimes no single explanation for altered mental status can be identified. Frequently, an acute medical illness exacerbates the confusion of patients with dementia, essentially creating both acute and chronic confusional states.",
"   </p>",
"   <p>",
"    The focus of this review is the differentiation of acute medical and neurological disorders from psychiatric causes of abnormal behavior in the emergency setting. The evaluation of the demented or agitated patient is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25962?source=see_link\">",
"     \"Assessment and management of the acutely agitated or violent adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered behavior and confusion are terms without strict medical definitions. A \"confused\" patient frequently comes to medical attention because in the judgment of someone (family, caregiver, observers, or police) some behavior is deemed unusual for the individual or deviates from societal norms. Less commonly do patients complain of confusion, consistent with the frequent lack of insight into their altered behavior. Delirium is an acute change in attention and mental functioning, and the formal definition includes disturbance of wake-sleep cycles and fluctuating confusion. Dementia is a chronic confusional state with insidious onset. The two conditions can and frequently do coexist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential causes of confusion and altered behavior are many and may reflect systemic illness, isolated organ system dysfunction, drug intoxications or withdrawal, psychiatric illness, or neurologic disease (",
"    <a class=\"graphic graphic_table graphicRef64699 \" href=\"mobipreview.htm?41/29/42459\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/2\">",
"     2",
"    </a>",
"    ]. A systematic approach to the patient with altered behavior looks first at states of diminished consciousness and then for neurologic disorders with any acute focal neurologic deficit. If either is present, that chief complaint directs the diagnostic approach. For the patient with altered behavior who is awake, alert, and without neurologic deficit, a formal assessment of attention span and cognitive ability may help to distinguish confusion or delirium from primary psychiatric complaints (",
"    <a class=\"graphic graphic_algorithm graphicRef77387 \" href=\"mobipreview.htm?42/57/43933\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Mental status testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Life-threatening conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chief complaint of confusion or isolated abnormal mental status implies stable vital signs and excludes many life-threatening conditions. Patients with abnormal behavior are screened for hypoxia and hypoglycemia by bedside testing. If present, treatment is provided and the cause investigated. Sepsis most often presents with fever, but not all patients manifest fever and some may be hypothermic. Hypertensive encephalopathy is a diagnosis of exclusion, but if suspected should prompt reduction of blood pressure. Wernicke's encephalopathy, also uncommon, occurs in patients with alcoholism or chronic malnutrition and is treated empirically with thiamine. Patients with drug overdoses also frequently present with altered behavior. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=see_link\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/62/10217?source=see_link\">",
"     \"Wernicke's encephalopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute neurologic disorders, such as meningitis and subarachnoid hemorrhage, may present with confusion, but headache or fever is more common. Acute or delayed presentations of central nervous system trauma, such as subdural hematoma, can manifest as confusion. Seizures may present with confusion, usually transient, in the postictal state, though some seizure types may present without convulsions as an ongoing confusional state. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6936?source=see_link\">",
"     \"Subdural hematoma in adults: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link\">",
"     \"Concussion and mild traumatic brain injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=see_link\">",
"     \"Status epilepticus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Common conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent disorders causing altered behavior are common systemic disorders, such as urinary tract infections or pneumonia. The elderly, particularly those with some chronic cognitive impairment, are the most vulnerable. Medication adverse effects and drug interactions also commonly manifest as confusion in the elderly (",
"    <a class=\"graphic graphic_table graphicRef70449 \" href=\"mobipreview.htm?1/11/1214\">",
"     table 2",
"    </a>",
"    ). Alcohol and medication withdrawal syndromes are other common diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=see_link&amp;anchor=H16#H16\">",
"     \"Drug prescribing for older adults\", section on 'Drug-drug interactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychiatric disorders such as depression, bipolar disorder, and schizophrenia represent another group of patients presenting to the emergency department (ED) with altered behavior. Patients with dementia who develop a systemic illness can present with an acute change in behavior. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually every medical condition is capable of causing confusion. Any condition causing electrolyte disturbances, including endocrine diseases, can present with confusion. Thyroid disease, myocardial infarction, strokes without motor deficits, and CNS mass lesions may all present with altered mental status, though typical presentations of these conditions are more common. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/1/36889?source=see_link\">",
"     \"Acute toxic-metabolic encephalopathy in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Life-threatening conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first challenge facing the emergency clinician is to define what is meant by altered behavior or confusion and to ascertain why this behavior led to the emergency department (ED) visit. Discussion with eyewitnesses is ideal. The specific behavior that led to the ED visit must be explored. Previous medical or psychiatric history from family, caregivers, clinicians, or medical records may hold the key to diagnosis.",
"   </p>",
"   <p>",
"    The second issue is to determine whether the problem concerns disorientation or memory difficulty or rather abnormal thought content. Disorientation and memory problems suggest medical or neurologic illness while disorders of thought content suggest psychiatric illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/4\">",
"     4",
"    </a>",
"    ]. Hallucinations, if present, are frequently auditory in psychiatric illnesses and visual with medical causes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28583?source=see_link\">",
"     \"Overview of psychosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Time of onset of the behavior, suspected precipitants, and a history of previous similar episodes are important facts. Schizophrenia and bipolar disorder frequently recur. New onset psychiatric illness typically begins in the teen and young adult years. Dementia is a disorder of the elderly; a specific time of onset is often difficult to identify. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historical factors associated with medical causes of abnormal behavior include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preexisting medical problems (eg, diabetes mellitus, seizure disorder)",
"     </li>",
"     <li>",
"      Absence of a known psychiatric diagnosis",
"     </li>",
"     <li>",
"      Use of psychoactive drugs of abuse (eg, hallucinogens)",
"     </li>",
"     <li>",
"      Use of prescription drugs with psychoactive properties, particularly in elders",
"     </li>",
"     <li>",
"      Late age of onset (&gt;40 years)",
"     </li>",
"     <li>",
"      Presence of symptoms that are sudden in onset and that fluctuate over hours to days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of particular interest are current medications, recent changes in medications, or any history of substance abuse. Withdrawal syndromes as well as active substance abuse may cause alterations in behavior. Particularly among older patients, medical ailments and drug interactions are common causes (",
"    <a class=\"graphic graphic_table graphicRef64699 \" href=\"mobipreview.htm?41/29/42459\">",
"     table 1",
"    </a>",
"    ). Obtaining basic screening tests in elderly patients is prudent. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Ancillary studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The rate of symptom onset may provide insight. Altered behavior from medical causes tends to be of acute onset and may occur at any age. Psychiatric illness may have an onset over weeks to months and tends to occur in younger adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;General physical examination helps to determine whether the cause of the altered behavior is a systemic problem, a problem of the central nervous system, or a psychiatric disorder.",
"   </p>",
"   <p>",
"    First the vital signs are reviewed. Patients with behavioral disorders usually have normal vital signs unless they are acutely agitated or suffering from a coexistent medical disorder. The presence of a fever suggests that an infectious process may be responsible for the altered behavior. Among elderly patients, any abnormal temperature raises concern for infection. Tachypnea or tachycardia may suggest the possibility of an infectious process or other systemic disorder.",
"   </p>",
"   <p>",
"    Next, a general physical examination is performed. Patients with behavioral disorders usually have an unremarkable physical examination, although signs of dehydration or neglect of chronic medical problems (eg, old wounds or skin infections) may be evident. Abnormal respiratory signs such as wheezes or crackles suggest pulmonary or cardiac disease, which can cause altered behavior from hypoxia, hypercarbia, or infection. Findings such as abdominal tenderness, jaundice, or signs of trauma direct further investigations.",
"   </p>",
"   <p>",
"    Structural problems of the central nervous system or systemic medical problems are more likely to cause a diminished level of consciousness than psychiatric illness.",
"   </p>",
"   <p>",
"    The presence of a toxidrome should prompt investigation of a toxic ingestion or medication interaction (ie, toxidromes) (",
"    <a class=\"graphic graphic_table graphicRef71268 \" href=\"mobipreview.htm?43/6/44140\">",
"     table 3",
"    </a>",
"    ). Toxidromes may include confusion in addition to abnormalities of vital signs. Nystagmus may be present in patients with intoxication from ethanol, sedative-hypnotic drugs, and other medications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A neurologic examination is performed to look for findings that suggest structural abnormalities of the brain. Aphasia is a focal neurologic finding, and though nonfluent aphasias are not difficult to recognize, a fluent aphasia with word-substitutions may go unrecognized in the ED. Asking the patient to name objects, read a sentence, and repeat a phrase may be useful to detect such aphasia. Neglect syndromes, especially visual neglect syndromes from parietal-occipital strokes, may be particularly difficult to discern. Performing confrontation testing of visual fields or observing the patient walk may be helpful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MENTAL STATUS TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient is awake, alert, with unremarkable vital signs, and without focal neurologic deficit, an assessment of mental status including attention span is in order. We suggest such patients be screened initially in the emergency department (ED) with the Six-Item Screen (SIS) or the Quick Confusion Scale (QCS), which are described below. Patients with a SIS score below 5 or a QCS score below 15 should be assessed for underlying medical (ie, nonpsychiatric) illness or medication-related problems. Patients with normal screening results should be assessed for psychiatric disorders. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Approach to diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Mental status testing is an assessment of the emotional and intellectual state of the individual at the moment of the examination. Mental status testing is often done informally in the ED, which can increase the risk of missing important findings. A detailed discussion of the mental status examination is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23303?source=see_link\">",
"     \"The mental status examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A formal structure for mental status testing consists of six elements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Appearance, affect, and attitude",
"     </li>",
"     <li>",
"      Disorders of thought",
"     </li>",
"     <li>",
"      Disorders of perception",
"     </li>",
"     <li>",
"      Mood and affect",
"     </li>",
"     <li>",
"      Insight and judgment",
"     </li>",
"     <li>",
"      Sensorium and intelligence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disorders of thought include delusions or hallucinations. Auditory hallucinations are more common in psychiatric disorders, while visual and other hallucinations suggest the possibility of neurologic or medical disorders.",
"   </p>",
"   <p>",
"    The presence of an attention deficit and short-term memory problem is the key finding in confusional states. The ability to shift attention and incorporate new information is necessary for daily functioning. The inability to perform these tasks represents the most common symptom of confusion.",
"   </p>",
"   <p>",
"    Many patients with psychiatric disorders, such as depression or bipolar disorder, preserve the ability to maintain attention and perform cognitive functions, while patients with medical or neurologic disorders do not. There are exceptions to this principle, most notably in the presence of psychosis. Depression, schizophrenia, or bipolar disorder may be so severe that the normal relationship with the environment is disrupted by hallucinations or delusions. Cognitive testing may be altered or even impossible to perform in such cases.",
"   </p>",
"   <p>",
"    A variety of simple tests have been recommended for assessing attention. Simple digit repetition, with or without reversal of those digits, is commonly used. Most people can easily repeat 6 or 7 digits, and can easily reverse 4 digits. Spelling \"WORLD\" backwards, or alphabetizing the letters in \"WORLD\" is also used as a screen for attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mini-mental status examination (MMSE) is commonly used to screen for cognitive problems by mental health personnel, and allows a rough quantification of attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/7\">",
"     7",
"    </a>",
"    ]. However, it may be difficult to use in the ED. The MMSE is a screen for dementia and consists of tasks assessing orientation, registration, attention, calculation, following a three-step command, and design copy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of cognitive impairment and dementia\", section on 'Cognitive testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Quick Confusion Scale (QCS) represents another attempt to quantify the attention aspects of mental status (",
"    <a class=\"graphic graphic_table graphicRef70343 \" href=\"mobipreview.htm?21/21/21852\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The QCS and MMSE were found to have significant correlation in one study of a convenience sample of 205 ED patients with abnormal behavior not attributable to trauma or acute illness. The QCS can be administered more quickly than the MMSE and does not require a constructional task.",
"   </p>",
"   <p>",
"    The Six-Item Screener (SIS) is another brief test of cognition (",
"    <a class=\"graphic graphic_table graphicRef58243 \" href=\"mobipreview.htm?1/11/1211\">",
"     table 5",
"    </a>",
"    ) found to be 94 percent sensitive (95% CI 73-100) and 86 percent specific (95% CI 74-94) in identifying cognitive impairment in older ED patients, when compared with the MMSE in a prospective randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/11\">",
"     11",
"    </a>",
"    ]. The SIS consists of six simple questions administered in a three step process. The patient is: given three items to remember (eg, apple, table, and penny) and asked to repeat them back to the examiner; asked to state the current year, month and day of week; asked to repeat the original three items. One point is given for each correct answer; a score below five connotes cognitive impairment.",
"   </p>",
"   <p>",
"    A number of other screening tests for cognitive dysfunction in elderly emergency department patients have been evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/12\">",
"     12",
"    </a>",
"    ]. All screening tests may be influenced by patient literacy, native intelligence, and environmental surroundings, and assess just a small part of the mental status of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANCILLARY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information from the medical history and physical examination is used to guide laboratory evaluation and other diagnostic tests obtained in the emergency department (ED). The causes of altered mental status are numerous, and indiscriminate testing is neither cost-effective nor efficient. Batteries of tests in patients who are awake and alert with normal vital signs seldom aid diagnosis, unless directed by the history and physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef57512 \" href=\"mobipreview.htm?34/52/35662\">",
"     algorithm 2",
"    </a>",
"    ) demonstrates one testing strategy. We suggest that a finger stick glucose and oxygenation measurement be obtained immediately at the bedside in any patient with an altered mental status. If the patient has a diminished level of consciousness, basic electrolytes, a complete blood count (CBC), and renal function tests should also be obtained.",
"   </p>",
"   <p>",
"    Appropriate laboratory investigations looking for a source of infection are performed in patients with fever or other signs of infection. An electrocardiogram (ECG), urinalysis, and chest x-ray (CXR) are routinely performed, particularly in elderly patients. If indicated, a CT scan of the head is useful to look for acute intracranial hemorrhage or other mass lesions. Focused toxicologic testing may be useful, if indicated by history or physical examination.",
"   </p>",
"   <p>",
"    If the altered mental status persists and the cause remains unclear, additional testing may be needed, including: arterial blood gas, thyroid studies, cerebrospinal fluid analysis, or cardiac biomarkers. As ED lengths of stay increase, the distinction between ED and inpatient workups has blurred, and more detailed investigations may be performed in the ED. Such testing may include an electroencephalogram (EEG), magnetic resonance imaging (MRI), and even brain biopsy. Obviously, such testing must be coordinated among emergency clinicians, consultants, and admitting clinicians.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The algorithm provided outlines an approach for the patient with altered mental status (",
"    <a class=\"graphic graphic_algorithm graphicRef77387 \" href=\"mobipreview.htm?42/57/43933\">",
"     algorithm 1",
"    </a>",
"    ). This approach involves four core questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is there a diminished level of consciousness?",
"     </li>",
"     <li>",
"      Is there an acute neurologic deficit?",
"     </li>",
"     <li>",
"      Is there an acute attention deficit or short-term memory problem (ie, confusion)?",
"     </li>",
"     <li>",
"      Is there evidence of infection or other acute medical illness?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with a diminished level of consciousness are quickly identified and assigned a different diagnostic strategy. Likewise, patients with focal neurologic deficits are evaluated in a different manner, looking for a stroke or mass lesion of the central nervous system. Confused patients with a fever or other signs of infection or systemic disease receive an appropriate workup.",
"   </p>",
"   <p>",
"    Patients who do not fall into any of these three categories may have a psychiatric or medical reason for their altered behavior. Focused testing of attention and cognition is helpful in these patients. We suggest using either the Six-Item Screen or the Quick Confusion Scale for such screening. For many patients with psychiatric disorders, attention span and other cognitive testing is normal, but thought content is not. Abnormal attention span or cognitive testing suggests that a medical or neurologic etiology for altered behavior may be present. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Mental status testing'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT AND DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient and staff safety are foremost concerns. Most of the emergency department (ED) workup is directed at determining life-threatening and reversible causes of confusion (",
"    <a class=\"graphic graphic_algorithm graphicRef57512 \" href=\"mobipreview.htm?34/52/35662\">",
"     algorithm 2",
"    </a>",
"    ). If confusion or abnormal behavior persists, the emergency clinician attempts to determine the nature of the confusion with assistance from the appropriate consultation or admitting service. Patients with suspected primary psychiatric issues are evaluated by psychiatrists or other mental health personnel consistent with local practice patterns. Patients with suspected or identified medical or neurological disorders are admitted to the appropriate ward under the care of primary care clinicians, internists, or neurologists. If the confusion resolves and appropriate care can be provided as an outpatient, the patient may be discharged. Social service consultation may be useful.",
"   </p>",
"   <p>",
"    At times, control of behavioral problems is necessary in the ED. Environmental manipulation (eg, quiet room, calm conversation) is the first approach, but sedative agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    may be necessary for patient and staff protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34311/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25962?source=see_link\">",
"     \"Assessment and management of the acutely agitated or violent adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/54/8034?source=see_link\">",
"       \"Patient information: Delirium (confusion) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/57/11155?source=see_link\">",
"       \"Patient information: Delirium (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104342079\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Altered behavior and confusion are terms without strict medical definitions. A \"confused\" patient frequently comes to medical attention because in the judgment of someone (family, caregiver, observers, or police) some behavior is deemed unusual for the individual or deviates from societal norms. Delirium is an acute change in attention and mental functioning; dementia is a chronic confusional state with insidious onset. The two conditions can and frequently do coexist. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link\">",
"       \"Evaluation of cognitive impairment and dementia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=see_link\">",
"       \"Diagnosis of delirium and confusional states\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The potential causes of confusion and altered behavior are many and may reflect systemic illness, isolated organ system dysfunction, drug intoxications or withdrawal, psychiatric illness, or neurologic disease. The accompanying table provides a list of life-threatening, common, and other potential causes of abnormal behavior (",
"      <a class=\"graphic graphic_table graphicRef64699 \" href=\"mobipreview.htm?41/29/42459\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When obtaining the history, the first issue is to determine the nature of the abnormal behavior. Important elements to consider include the onset and time course of the altered behavior, associated symptoms, previous medical and psychiatric illness, medication use, and illicit drug use. The second issue is to determine whether the problem concerns disorientation or memory difficulty or rather abnormal thought content. Disorientation and memory problems suggest medical or neurologic illness while disorders of thought content suggest psychiatric illness. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination helps to determine whether the cause of the altered behavior is a systemic problem, a problem of the central nervous system, or a psychiatric disorder. Patients with behavioral disorders usually have an unremarkable physical examination. Of particular importance are abnormal vital signs, depressed level of consciousness, signs of a toxidrome, and focal neurologic deficits (eg, aphasia). If a patient is awake, alert, with unremarkable vital signs, and without focal neurologic deficit, an assessment of mental status including attention span is in order. Techniques for assessing mental status, such as the Six-Item Screen and the Quick Confusion Scale, are described in the text. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Mental status testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Findings from the medical history and physical examination determine what diagnostic tests are obtained. Indiscriminate testing is counterproductive and wasteful. A finger stick glucose and oxygenation saturation measurement should be obtained immediately at the bedside for any patient with an altered mental status. One suggested approach to testing is described in the attached algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef57512 \" href=\"mobipreview.htm?34/52/35662\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ancillary studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The algorithm provided outlines an approach for the patient with abnormal behavior (",
"      <a class=\"graphic graphic_algorithm graphicRef77387 \" href=\"mobipreview.htm?42/57/43933\">",
"       algorithm 1",
"      </a>",
"      ). This approach involves four core questions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Is there a diminished level of consciousness?",
"     </li>",
"     <li>",
"      Is there an acute neurologic deficit?",
"     </li>",
"     <li>",
"      Is there an acute attention deficit or short-term memory problem (ie, confusion)?",
"     </li>",
"     <li>",
"      Is there evidence of infection or other acute medical illness?",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34311/abstract/1\">",
"      Hustey FM, Meldon SW. The prevalence and documentation of impaired mental status in elderly emergency department patients. Ann Emerg Med 2002; 39:248.",
"     </a>",
"    </li>",
"    <li>",
"     Huff JS. Confusion. In: Emergency Medicine: A Comprehensive Study Guide, Tintnalli JE, Stapczynski JS, Cline DM, et al.  (Eds), McGraw-Hill, New York 2011. p.1135.",
"    </li>",
"    <li>",
"     Huff JS. Confusion. In: Rosen's Emergency Medicine: Concepts and Clinical Practice, Marx JA, Hockberger RS, Walls RM.  (Eds), Elsevier Health Sciences, Philadelphia 2010. p.101.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34311/abstract/4\">",
"      Talbot-Stern JK, Green T, Royle TJ. Psychiatric manifestations of systemic illness. Emerg Med Clin North Am 2000; 18:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34311/abstract/5\">",
"      Zun L, Gold I. A survey of the form of the mental status examination administered by emergency physicians. Ann Emerg Med 1986; 15:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34311/abstract/6\">",
"      Leopold NA, Borson AJ. An alphabetical 'WORLD'. A new version of an old test. Neurology 1997; 49:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34311/abstract/7\">",
"      Folstein MF, Folstein SE, McHugh PR. \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34311/abstract/8\">",
"      Huff JS, Farace E, Brady WJ, et al. The quick confusion scale in the ED: comparison with the mini-mental state examination. Am J Emerg Med 2001; 19:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34311/abstract/9\">",
"      Irons MJ, Farace E, Brady WJ, Huff JS. Mental status screening of emergency department patients: normative study of the quick confusion scale. Acad Emerg Med 2002; 9:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34311/abstract/10\">",
"      Kaufman DM, Zun L. A quantifiable, Brief Mental Status Examination for emergency patients. J Emerg Med 1995; 13:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34311/abstract/11\">",
"      Wilber ST, Lofgren SD, Mager TG, et al. An evaluation of two screening tools for cognitive impairment in older emergency department patients. Acad Emerg Med 2005; 12:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34311/abstract/12\">",
"      Carpenter CR, Bassett ER, Fischer GM, et al. Four sensitive screening tools to detect cognitive dysfunction in geriatric emergency department patients: brief Alzheimer's Screen, Short Blessed Test, Ottawa 3DY, and the caregiver-completed AD8. Acad Emerg Med 2011; 18:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34311/abstract/13\">",
"      American College of Emergency Physicians. Clinical policy for the initial approach to patients presenting with altered mental status. Ann Emerg Med 1999; 33:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34311/abstract/14\">",
"      Inouye SK. Delirium in older persons. N Engl J Med 2006; 354:1157.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 289 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-8C22B84DCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34311=[""].join("\n");
var outline_f33_32_34311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H104342079\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Life-threatening conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Common conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MENTAL STATUS TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANCILLARY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      APPROACH TO DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT AND DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104342079\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/289\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/289|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?42/57/43933\" title=\"algorithm 1\">",
"      Abnormal adult behavior diagnosis algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?34/52/35662\" title=\"algorithm 2\">",
"      Abnormal adult behavior management algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/289|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/29/42459\" title=\"table 1\">",
"      Differential diagnosis of abnormal adult behavior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/11/1214\" title=\"table 2\">",
"      Drugs that cause or prolong delirium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/6/44140\" title=\"table 3\">",
"      Poisoning syndromes - toxidromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/21/21852\" title=\"table 4\">",
"      Rapid screen for confusion in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/11/1211\" title=\"table 5\">",
"      Six item screen for confusion in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/1/36889?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/0/30730?source=related_link\">",
"      Drug prescribing for older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/39/24184?source=related_link\">",
"      Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/57/11155?source=related_link\">",
"      Patient information: Delirium (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/54/8034?source=related_link\">",
"      Patient information: Delirium (confusion) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6936?source=related_link\">",
"      Subdural hematoma in adults: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23303?source=related_link\">",
"      The mental status examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/62/10217?source=related_link\">",
"      Wernicke's encephalopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_32_34312="Dialysis modality and patient outcome";
var content_f33_32_34312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dialysis modality and patient outcome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/32/34312/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/32/34312/contributors\">",
"     Lionel U Mailloux, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/32/34312/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/32/34312/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/32/34312/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/32/34312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/32/34312/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/32/34312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the life expectancy of patients with end-stage renal disease has improved since the introduction of dialysis in the 1960s, it is still far below that of the general population. As an example, according to the 2012 ESRDS report, the rate of all-cause mortality is 6.3 to 8.2 times greater for dialysis patients compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, one partial explanation for the poor survival in the United States was inadequate dialysis, since substantially higher survival rates have been reported in Europe and Japan even after case adjustment for age, sex, and renal diagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/2\">",
"     2",
"    </a>",
"    ]. Japanese patients, for example, have far fewer comorbid risk factors than those in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, it is more likely that factors such as older age, a higher prevalence of diabetes mellitus, more comorbid conditions and inability to accurately capture severity of any noted comorbid disease are components of the higher dialysis mortality in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/5\">",
"     5",
"    </a>",
"    ]. This is particularly true as an increasing dialysis dose has been realized in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the highest survival rates has been reported from Tassin, France where patients are dialyzed 24 hours per week, much longer than in almost all other centers (",
"    <a class=\"graphic graphic_figure graphicRef53811 \" href=\"mobipreview.htm?42/40/43661\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/6\">",
"     6",
"    </a>",
"    ]. This, and other observations, has led to a general increase in time in the dialysis prescription in the United States.",
"   </p>",
"   <p>",
"    In addition to increased duration of dialysis, it has been proposed that other factors also may improve patient outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic reviews the selection of dialysis modality and patient outcomes that are associated with specific modalities. Patient outcomes associated with dialysis adequacy, the use of daily or nocturnal hemodialysis and the selection of different types of peritoneal dialysis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18137?source=see_link\">",
"     \"Short daily hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33530?source=see_link\">",
"     \"Sustained low efficiency or extended daily dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/24/3465?source=see_link\">",
"     \"Outcomes associated with nocturnal hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31286?source=see_link\">",
"     \"Choosing a modality for chronic peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SELECTION OF DIALYSIS MODALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis modalities include hemodialysis, either in a dialysis center or at home, or peritoneal dialysis including chronic ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). In Europe, some patients are treated with hemofiltration technologies.",
"   </p>",
"   <p>",
"    The percentage of patients undergoing hemodialysis far surpasses those being maintained on peritoneal dialysis. Based on the 2009 USRDS report, 94 and 6 percent began hemodialysis and peritoneal dialysis in the United States, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/5\">",
"     5",
"    </a>",
"    ]. Approximately 11 percent of dialysis patients worldwide are treated with peritoneal dialysis, with the relative proportion increasing in developing, but not developed countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/7\">",
"     7",
"    </a>",
"    ]. About 2.5 percent of patients with end-stage renal disease received a renal transplant as the initial treatment for their end-stage renal disease. Hemodialysis is generally more expensive than peritoneal dialysis. In 2006, Medicare expenditures for HD were $71,889 per patient per year compared to $53,327 for those on peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients can be treated with either peritoneal dialysis or hemodialysis. The selection of dialysis modality is influenced by a number of considerations such as availability and convenience, comorbid conditions, socioeconomic and dialysis center factors, the patient's home situation, method of physician reimbursement, and the ability to tolerate volume shifts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/9-15\">",
"     9-15",
"    </a>",
"    ]. Patients generally like to have a choice of modalities. As an example, in the Netherlands study cited above, in which among 738 eligible patients, only 38 agreed to be randomly assigned to a specific therapy, 50 percent of patients chose peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are selected for peritoneal dialysis may have fewer co-morbidities compared with those who undergo hemodialysis. This was best shown in the CHOICE cohort study in which the baseline characteristics of 279 and 759 incident peritoneal dialysis and hemodialysis patients, respectively, were assessed using the index of coexistent diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/17\">",
"     17",
"    </a>",
"    ]. Comorbidity was significantly less severe among peritoneal dialysis patients, with the odds ratio of choosing PD being much less for those with the most severe coexistent conditions (odds ratio of 0.50, 95% CI 0.28-0.90).",
"   </p>",
"   <p>",
"    Other studies that have examined this issue have yielded conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. However, many of these reports, particularly those in the United States, were flawed because comorbidity was commonly assessed among prevalent (and not incident) patients and was principally defined as the relative contributions from age, diabetes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the underlying cause of renal disease.",
"   </p>",
"   <p>",
"    Among some patients it may be optimal to utilize both hemodialysis and peritoneal dialysis in a way that provides the advantages of each modality, but without the disadvantages. An optimal strategy, for example, may be an integrated care approach in which incident dialysis patients initially undergo peritoneal dialysis, with transfer to hemodialysis once complications ensue with peritoneal dialysis. This is based in part on the hypothesis that, principally via its ability to preserve residual renal function, peritoneal dialysis provides significant benefits as an initial modality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Other benefits may include preservation of vascular access and perhaps better survival during the first few years of dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Peritoneal dialysis versus in-center hemodialysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SURVIVAL BY MODALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, in 2009 approximately 94 percent of prevalent ESRD patients were treated with in-center hemodialysis and 6 percent with peritoneal dialysis, which is a different modality distribution from that observed in other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/5\">",
"     5",
"    </a>",
"    ]. Many observational studies have attempted to compare outcomes among patients on in-center hemodialysis versus peritoneal dialysis. Our opinion is that for most patients dialyzing at a center that is equally qualified to provide both in-center hemodialysis and peritoneal dialysis, the expected outcomes for either modality would be similar. The following is an overview of some of the relative survival data related to the different currently available chronic dialysis modalities:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Peritoneal dialysis versus in-center hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of studies, practically all retrospective and observational, have been performed concerning the relative effect upon mortality of peritoneal dialysis versus in-center hemodialysis. The results have been conflicting, with hemodialysis reportedly having no difference, a relative benefit, or a relative adverse effect upon survival compared with peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/25-34\">",
"     25-34",
"    </a>",
"    ]. Reasons for these variable results include selection bias, flawed study design, differences in mortality effects with time from initiation of dialysis, differences in co-morbid diseases, and other factors.",
"   </p>",
"   <p>",
"    Multiple studies have found that peritoneal dialysis may provide relative short-term survival benefits but comparable or decreased survival after one to two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/35-41\">",
"     35-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An intention to treat analysis of 35,265 Canadian patients who initiated dialysis between 1991 and 2004 demonstrated better survival associated with peritoneal dialysis for the first 18 months, and with hemodialysis after 36 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/42\">",
"       42",
"      </a>",
"      ]. Analysis of patients who started dialysis between 2001 and 2004 showed better survival with peritoneal dialysis for two years and comparable survival thereafter.",
"     </li>",
"     <li>",
"      One study from the Canadian registry using an \"as-treated\" analysis (in which treatment modality switches were incorporated) found that",
"      <span class=\"nowrap\">",
"       CAPD/CCPD,",
"      </span>",
"      compared with hemodialysis, was associated with a significantly lower risk of death (relative risk of 0.73) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/35\">",
"       35",
"      </a>",
"      ]. Most of the survival benefit was observed during the first two years after the initiation of renal replacement therapy. By comparison, the survival benefit of peritoneal dialysis largely disappeared (hazard ratio 0.93) with an \"intent-to-treat\" analysis (in which treatments were classified based upon modality 90 days post-initiation).",
"     </li>",
"     <li>",
"      An advantage in short-term but not long-term survival with",
"      <span class=\"nowrap\">",
"       CAPD/CCPD",
"      </span>",
"      was also noted in a study of incident patients in the United States (99,048 hemodialysis and 18,110",
"      <span class=\"nowrap\">",
"       CAPD/CCPD",
"      </span>",
"      patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/36\">",
"       36",
"      </a>",
"      ]. Compared with patients undergoing hemodialysis, Cox regression analysis found that the relative risk of death for",
"      <span class=\"nowrap\">",
"       CAPD/CCPD",
"      </span>",
"      in nondiabetic and diabetic patients was 0.62 and 0.73 at three months, respectively; however, there was no significant difference in risk at two years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Analysis of data provided by the United States Renal Data Systems (USRDS) also suggested a survival benefit associated with peritoneal dialysis during the first few years on dialysis but which was lost over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients on peritoneal dialysis had a slight overall survival advantage compared to those on hemodialysis during the first three years of therapy, but at five years, survival was equal at 34 percent (",
"    <a class=\"graphic graphic_figure graphicRef83660 \" href=\"mobipreview.htm?1/21/1375\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These observations are not confined to the United States. There are similar trends in review of data from Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/33\">",
"     33",
"    </a>",
"    ], Northern Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/37,39\">",
"     37,39",
"    </a>",
"    ], and from Australia and New Zealand (ANZDATA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time after dialysis initiation at which the relative survival benefit associated with peritoneal dialysis is lost and survival comparisons start to favor hemodialysis depends on multiple variables, including the cause of end-stage renal disease (ESRD), vintage (ie, the year patient started renal replacement therapy), gender, country of treatment, and presence or absence of co-morbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. As an example, the survival advantage conferred by peritoneal dialysis is not as robust if the primary case of ESRD is diabetes, the patient is elderly, or if the patient has co-morbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/39,40,45-48\">",
"     39,40,45-48",
"    </a>",
"    ]. In one study that analyzed data from 398,940 patients who initiated dialysis between the years 1995 to 2000 mortality risk was higher with hemodialysis than peritoneal dialysis among those who had no baseline comorbidity (with relative risks of 1.24, 1.13, and 1.13 among those between 18 to 44, 45 to 64, and older than 65 years, respectively), and among younger diabetics with no comorbidity (relative risk, 1.22, for age between 18 and 44 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/45\">",
"     45",
"    </a>",
"    ]. By comparison, hemodialysis was associated with a lower mortality risk in older diabetics with either no comorbidity (relative risk of 0.92 and 0.86 for ages 45 to 64 and greater than 65 years, respectively) or a baseline comorbidity (relative risk 0.82 and 0.80 for ages 45 to 64 and greater than 65 years, respectively).",
"   </p>",
"   <p>",
"    The presence of heart failure may also attenuate the early survival benefit associated with peritoneal dialysis. Although one study found one- and two-year survivals of 90 and 64 percent among peritoneal dialysis patients with severe systolic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/46\">",
"     46",
"    </a>",
"    ], a subsequent study found poorer survival among new dialysis patients with heart failure who were initially treated with peritoneal dialysis compared with hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the major limitations of these epidemiologic studies is that there is an age by modality interaction. In particular, the risk of death with modality varies with age, with peritoneal dialysis having a relatively increased and decreased mortality in older and younger patients, respectively. Overall, it appears that the variable results are due to differences among incident patients and the type of analytical method utilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Matched cohort studies have attempted to address some of these shortcomings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/40,50,51\">",
"     40,50,51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study (CHOICE) compared the risk of death among 1041 patients starting dialysis (274 and 767 receiving peritoneal dialysis and hemodialysis, respectively) who were followed for up to seven years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/50\">",
"       50",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      After statistical adjustment, the risk of death at one year from dialysis initiation was similar with both modalities. In the second year, however, the risk of death was significantly higher with peritoneal dialysis (hazard ratio [HR] 2.34, 95% CI 1.19-4.59). This result was consistently observed with different statistical models, including a propensity score model and variations in sensitivity analysis. With subgroup analysis, a higher risk of death with peritoneal dialysis was observed in patients with cardiovascular disease and those with an intermediate propensity score of being initially treated with PD. Unlike other studies, an increase risk for death with PD was not observed among patients with diabetes or cardiovascular disease or older patients. However, the overall mortality was relatively low for hemodialysis patients suggesting that the cohort may not be representative of the US as a whole.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another retrospective cohort study analyzed 6337 matched patient pairs who initiated dialysis in the United States during 2003 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/51\">",
"       51",
"      </a>",
"      ]. In an intention-to-treat analysis, compared with hemodialysis patients, cumulative survival was higher for peritoneal dialysis patients (HR 0.92, 95% CI 0.86-1.00).",
"      <br/>",
"      <br/>",
"      Cumulative survival probabilities for peritoneal versus hemodialysis were 85.8 versus 80.7 percent, 71.1 versus 68.0 percent, 58.1 versus 56.7 percent and 48.4 percent versus 47.3 percent at 12, 24, 36 and 48 months, respectively. The survival advantage for PD was most robust in patients less than 65 years old, those with no cardiovascular disease, and those without diabetes. If the observation was started at day 90, there was no difference between the modalities overall, but HD was associated with improved survival in patients with cardiovascular disease and diabetes.",
"     </li>",
"     <li>",
"      In a study of 27,015 patients from Australia and New Zealand, compared with hemodialysis, peritoneal dialysis was associated with a higher survival from day 90 to day 365 (HR 0.89, 95% CI 0.81-0.99) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/40\">",
"       40",
"      </a>",
"      ]. These benefits were most significant among younger patients without comorbid conditions. After one year, however, peritoneal dialysis was associated with markedly higher mortality (HR 1.33, 95% CI 1.24-1.42).",
"      <br/>",
"      <br/>",
"      However, a propensity-score analysis, (in which peritoneal dialysis patients were matched with hemodialysis patients with known covariates) showed no difference in mortality between groups prior to one year (HR 0.99, 95% CI 0.89-1.10) and an increase in mortality associated with peritoneal dialysis after one year (HR 1.35, 95% CI 1.27-1.42).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ideal method to compare survival on peritoneal dialysis and hemodialysis would be a prospective study that randomly assigned patients to peritoneal dialysis or in-center hemodialysis, and applied current knowledge to all enrolled patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/16,52-54\">",
"     16,52-54",
"    </a>",
"    ]. An attempt to perform such a study was initiated in the Netherlands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/16\">",
"     16",
"    </a>",
"    ]. However, among 738 patients who were eligible to participate, only 38 agreed to be randomized. Because of the small number of enrolled patients and of deaths (9 and 5 with hemodialysis and peritoneal dialysis, respectively) no significant survival data could be derived from this trial. Unfortunately, this study suggests that an appropriately powered trial to answer this important question will be extremely difficult to perform.",
"   </p>",
"   <p>",
"    Survival on peritoneal dialysis may be improving. According to the 2009 USRDS report, overall five-year survival continued to improve such that patients who started dialysis from 1998 to 2002 had a 7.5 percent increase in survival from that seen for patients who started dialysis from 1993 to 1997 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/43\">",
"     43",
"    </a>",
"    ]. Whereas there was 14.8 percent improvement in five-year survival for patients on peritoneal dialysis, there was only a 7.2 percent improvement for hemodialysis patients (",
"    <a class=\"graphic graphic_figure graphicRef83658 \" href=\"mobipreview.htm?10/35/10814\">",
"     figure 3",
"    </a>",
"    ). The 2012 USRDS report showed continued improvement in five-year survival for patients starting PD up until the last reported cohort in 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    USRDS data also suggest that the early benefit associated with peritoneal dialysis may be maintained for a longer period of time in recent years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/56\">",
"     56",
"    </a>",
"    ]. Whereas, among patients who started peritoneal dialysis between 1991 to 1995, survival was higher for peritoneal dialysis patients until 12 to 16 months but better among hemodialysis patients after that, among patients who started dialysis between 1996 and 2000, the survival advantage conferred by peritoneal dialysis was maintained for about 36 months.",
"   </p>",
"   <p>",
"    Possible reasons for the improved observed survival among peritoneal dialysis patients may be that earlier mortality studies were published before the widespread use of alternative peritoneal dialysate solutions and prior to the implementation of robust home dialysis programs, the latter which allow for refinement of clinician skills and establishment of continuous quality improvement (CQI) programs, which could improve patient outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/15,57\">",
"     15,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     High-flux and high-efficiency hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-efficiency refers to standard cellulosic membranes with a larger surface area, whereas high-flux refers to more porous noncellulosic membranes with increased permeability, particularly to larger molecules.",
"   </p>",
"   <p>",
"    These modalities may decrease morbidity (hypotension and symptoms such as nausea, vomiting, cramps, and headache) during dialysis. It has been proposed that biocompatible membranes produce fewer intradialytic symptoms due to the absence of complement activation and neutrophil aggregation.",
"   </p>",
"   <p>",
"    High-flux dialysis may have a number of long-term benefits, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enhanced beta2-microglobulin clearance and a possible reduction in late amyloid deposition. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5609?source=see_link\">",
"       \"Dialysis-related amyloidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An improvement in the lipid abnormalities commonly seen in renal failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"       \"Lipid abnormalities in nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With biocompatible membranes, less stimulation of neutrophils and monocytes due to less activation of complement and cytokines. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26902?source=see_link\">",
"       \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several nonrandomized observational studies suggesting that these and perhaps other factors may lead to higher patient survival with high-flux dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/58-62\">",
"     58-62",
"    </a>",
"    ]. The question of a possible survival benefit with high flux dialysis was best addressed in a large randomized clinical trial, called the Hemodialysis (HEMO) study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/63\">",
"     63",
"    </a>",
"    ]. In this report, 1846 patients were randomly assigned to a low-flux or high-flux dialyzer (based on clearance of beta-2-microglobulin) and a standard or high dose of dialysis. The primary outcome was death from any cause, while the main secondary outcomes were the rate of all hospitalizations (but excluding those related to access), and the composite outcomes of the first hospitalization for a cardiac problem or death from any cause, the first hospitalization for an infectious cause or death, and the first decline of greater than 15 percent of the serum albumin from baseline value or death. Issues relating to dialysis dose and survival in this study are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following results concerning survival and membrane flux were reported at a mean follow-up of 4.5 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impressive separation was obtained for the low and high flux groups, with clearances of beta-2-microglobulin of 3 and 34",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      The risk of death from any cause, the primary outcome, was the",
"      <strong>",
"       same",
"      </strong>",
"      in the high and low flux groups (RR of death of 0.92 for high versus low flux, 95% CI 0.81-1.05) (",
"      <a class=\"graphic graphic_figure graphicRef71570 \" href=\"mobipreview.htm?35/58/36781\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The risk of the main secondary outcomes was also the",
"      <strong>",
"       same",
"      </strong>",
"      for both flux groups. In the high flux group, there were significant reductions, compared with the low flux group, in the risk of death from cardiac causes and the combined outcome of hospitalizations or death from a cardiac cause. However, as previously mentioned, total mortality was the same in both groups.",
"     </li>",
"     <li>",
"      Subgroup analysis revealed a significant overall survival and cardiovascular survival benefit for patients with more than 3.7 years of dialysis receiving high flux dialysis (32 percent lower risk than the low flux group, CI 0.53-0.86). However, the strength of the interaction between the flux group and years of dialysis was weakened when years of dialysis were treated as a continuous variable or were further subdivided into five groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, although there does not appear to be an overall survival benefit with high-flux dialysis membranes, subgroup analysis suggests a possible benefit with high-flux dialysis among longer vintage dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/64\">",
"     64",
"    </a>",
"    ]. A similar finding showing a survival benefit with high flux membranes among those undergoing dialysis was noted in a retrospective study from France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/65\">",
"     65",
"    </a>",
"    ]. In this study, among 650 patients undergoing dialysis therapy for a mean period of 96 to 102 months, multivariate analysis revealed that survival was significantly higher among those undergoing dialysis with high flux membranes (relative risk of 0.62, 95% CI 0.43-0.91).",
"   </p>",
"   <p>",
"    A Cochrane systematic review and meta-analysis found that high-flux dialysis did not change all-cause mortality (10 studies, 2915 participants) but did decrease cardiovascular mortality (5 studies, 2612 participants, RR 0.83, 95% CI 0.70&ndash;0.99) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/66\">",
"     66",
"    </a>",
"    ]. The dialysis vintage varied between studies however and subgroup analysis of patients with increased vintage was not performed.",
"   </p>",
"   <p>",
"    Additional studies are required to confirm the suggested benefit of high flux membranes among dialysis patients of increasing vintage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Home, nocturnal, and short-daily hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observed survival is generally highest in patients treated with home hemodialysis: up to 89 percent at five years, 74 percent at 15 years in nondiabetics, and 50 percent at 15 years overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Despite this apparent advantage, the absolute number and relative percentage of patients with end-stage renal failure who use home hemodialysis in the United States has slowly declined over the last decade and is much lower than that in some other countries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19144?source=see_link\">",
"     \"Home hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nocturnal hemodialysis (eg, long-nightly-home hemodialysis, a form of quotidian hemodialysis) was introduced, principally in Canada, as a (possibly) more desirable alternative to conventional dialysis, since it provides quantitatively more dialysis based upon dose, duration, and frequency. This can be accomplished because it is performed during nightly sleep, an otherwise unproductive time.",
"   </p>",
"   <p>",
"    Based on better outcomes in many biochemical areas, quality of life issues, blood pressure control, regression of left ventricular hypertrophy, improved sleep patterns and improved general well being, one would expect improved survival rates of these patients. There now are prospective randomized trial data using cardiovascular endpoints as a surrogate for survival which suggests that survival is truly improved with these modalities with lower mortalities and similar survival rates to deceased donor renal transplants. For all these reasons, it is the authors&rsquo; opinion that nocturnal hemodialysis will be associated with improved patient survival since it provides the best clearance of uremic products along with remarkable hemodynamic stability (with only gradual changes in physiological parameters), and improved cardiovascular function with regression of left ventricular hypertrophy (which is a potent cardiovascular disease risk factor). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/24/3465?source=see_link\">",
"     \"Outcomes associated with nocturnal hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another modality is short hours high efficiency daily hemodialysis (another form of quotidian hemodialysis). This consists of hemodialysis occurring 5 to 6",
"    <span class=\"nowrap\">",
"     days/week",
"    </span>",
"    with a total duration of 1.5 to 2.5 hours per day. Limited data have suggested relatively better survival among patients on short daily hemodialysis compared with in-center conventional hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18137?source=see_link&amp;anchor=H28#H28\">",
"     \"Short daily hemodialysis\", section on 'Survival'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hemodialysis versus hemodiafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although virtually not used in the United States, hemodiafiltration is a form of chronic renal replacement therapy in Europe, particularly Germany and Belgium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34312/abstract/70\">",
"     70",
"    </a>",
"    ]. Based upon relatively better clearance of larger \"middle\" molecules, some claim that replacement therapy with hemodiafiltration may be superior to that with hemodialysis, including improved hemodynamics.",
"   </p>",
"   <p>",
"    Issues surrounding relative survival with these modalities are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/39/30330?source=see_link\">",
"     \"Alternative renal replacement therapies in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PRETRANSPLANTATION DIALYSIS MODALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues surrounding pretransplantation dialysis modality and outcomes post-renal transplantation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11224?source=see_link\">",
"     \"Dialysis issues prior to and after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dialysis modalities include hemodialysis, either in a dialysis center or at home, or peritoneal dialysis including chronic ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). In Europe, some patients are treated with hemofiltration technologies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Selection of dialysis modality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients can be treated with either peritoneal dialysis or hemodialysis. The selection of dialysis modality is influenced by a number of considerations such as availability and convenience, comorbid conditions, socioeconomic and dialysis center factors, the patient's home situation, method of physician reimbursement, and the ability to tolerate volume shifts. Among some patients it may be optimal to utilize both hemodialysis and peritoneal dialysis over the course of treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Selection of dialysis modality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with in-center hemodialysis, peritoneal dialysis may provide relative short-term survival benefits but comparable or decreased survival after the first few years. Co-morbidities such as diabetes or heart failure may attenuate the early relative benefit associated with peritoneal dialysis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Peritoneal dialysis versus in-center hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-flux dialysis may have a number of long-term benefits, including enhanced beta2-microglobulin clearance, improved lipid profiles and, with biocompatible membranes, less stimulation of neutrophils and monocytes. High flux dialysis does not improve survival, except possible among patients who have been on dialysis for many years. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'High-flux and high-efficiency hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with all other renal replacement modalities, survival is generally highest in patients treated with home hemodialysis. Despite this apparent advantage, the number of patients with end-stage renal failure who use home hemodialysis in the United States has slowly declined over the last decade and is much lower than that in some other countries. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Home, nocturnal, and short-daily hemodialysis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19144?source=see_link\">",
"       \"Home hemodialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nocturnal hemodialysis and short daily hemodialysis may be associated with improved patient survival compared with conventional in-center hemodialysis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Home, nocturnal, and short-daily hemodialysis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=see_link\">",
"       \"Technical aspects of nocturnal hemodialysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/24/3465?source=see_link\">",
"       \"Outcomes associated with nocturnal hemodialysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18137?source=see_link&amp;anchor=H28#H28\">",
"       \"Short daily hemodialysis\", section on 'Survival'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.usrds.org/atlas.aspx.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/2\">",
"      Introduction and summary. Proceedings from the Morbidity, Mortality and Prescription of Dialysis Symposium, Dallas, Tx, September 15 to 17, 1989. Am J Kidney Dis 1990; 15:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/3\">",
"      Iseki K, Kawazoe N, Osawa A, Fukiyama K. Survival analysis of dialysis patients in Okinawa, Japan (1971-1990). Kidney Int 1993; 43:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/4\">",
"      Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 1994; 23:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/5\">",
"      United States Renal Data System. Excerpts from the USRDS 2009 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2010; 1(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/6\">",
"      Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/7\">",
"      Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol 2012; 23:533.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Renal Data System, USRDS 2008 Annual Data Report. Atlas of Chronic Kidney and End-Stage Renal Disease in the United States, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/9\">",
"      Van Biesen W, Vanholder R, Lameire N. The role of peritoneal dialysis as the first-line renal replacement modality. Perit Dial Int 2000; 20:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/10\">",
"      Goldstein A, Kliger AS, Finkelstein FO. Recovery of renal function and the discontinuation of dialysis in patients treated with continuous peritoneal dialysis. Perit Dial Int 2003; 23:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/11\">",
"      Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/12\">",
"      Wauters JP, Uehlinger D. Non-medical factors influencing peritoneal dialysis utilization: the Swiss experience. Nephrol Dial Transplant 2004; 19:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/13\">",
"      Mendelssohn DC, Langlois N, Blake PG. Peritoneal dialysis in Ontario: a natural experiment in physician reimbursement methodology. Perit Dial Int 2004; 24:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/14\">",
"      Tonelli M, Hemmelgarn B, Culleton B, et al. Mortality of Canadians treated by peritoneal dialysis in remote locations. Kidney Int 2007; 72:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/15\">",
"      Mehrotra R, Khawar O, Duong U, et al. Ownership patterns of dialysis units and peritoneal dialysis in the United States: utilization and outcomes. Am J Kidney Dis 2009; 54:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/16\">",
"      Korevaar JC, Feith GW, Dekker FW, et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int 2003; 64:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/17\">",
"      Miskulin DC, Meyer KB, Athienites NV, et al. Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease. Am J Kidney Dis 2002; 39:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/18\">",
"      Maiorca R, Vonesh EF, Cavalli P, et al. A multicenter, selection-adjusted comparison of patient and technique survivals on CAPD and hemodialysis. Perit Dial Int 1991; 11:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/19\">",
"      Serkes KD, Blagg CR, Nolph KD, et al. Comparison of patient and technique survival in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis: a multicenter study. Perit Dial Int 1990; 10:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/20\">",
"      Gentil MA, Carriazo A, Pav&oacute;n MI, et al. Comparison of survival in continuous ambulatory peritoneal dialysis and hospital haemodialysis: a multicentric study. Nephrol Dial Transplant 1991; 6:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/21\">",
"      Blake PG. Integrated end-stage renal disease care: the role of peritoneal dialysis. Nephrol Dial Transplant 2001; 16 Suppl 5:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/22\">",
"      Mendelssohn DC, Pierratos A. Reformulating the integrated care concept for the new millennium. Perit Dial Int 2002; 22:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/23\">",
"      Kawanishi H, Moriishi M. Clinical effects of combined therapy with peritoneal dialysis and hemodialysis. Perit Dial Int 2007; 27 Suppl 2:S126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/24\">",
"      Panagoutsos S, Kantartzi K, Passadakis P, et al. Timely transfer of peritoneal dialysis patients to hemodialysis improves survival rates. Clin Nephrol 2006; 65:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/25\">",
"      Nelson CB, Port FK, Wolfe RA, Guire KE. Comparison of continuous ambulatory peritoneal dialysis and hemodialysis patient survival with evaluation of trends during the 1980s. J Am Soc Nephrol 1992; 3:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/26\">",
"      Held PJ, Port FK, Turenne MN, et al. Continuous ambulatory peritoneal dialysis and hemodialysis: comparison of patient mortality with adjustment for comorbid conditions. Kidney Int 1994; 45:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/27\">",
"      Tzamaloukas AH, Yuan ZY, Balaskas E, Oreopoulos DG. CAPD in end stage patients with renal disease due to diabetes mellitus--an update. Adv Perit Dial 1992; 8:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/28\">",
"      O'Donoghue D, Manos J, Pearson R, et al. Continuous ambulatory peritoneal dialysis and renal transplantation: a ten-year experience in a single center. Perit Dial Int 1992; 12:242, 245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/29\">",
"      Nissenson AR, Gentile DE, Soderblom RE, et al. Morbidity and mortality of continuous ambulatory peritoneal dialysis: regional experience and long-term prospects. Am J Kidney Dis 1986; 7:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/30\">",
"      Vonesh EF, Moran J. Mortality in end-stage renal disease: a reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1999; 10:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/31\">",
"      Murphy SW, Foley RN, Barrett BJ, et al. Comparative mortality of hemodialysis and peritoneal dialysis in Canada. Kidney Int 2000; 57:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/32\">",
"      Locatelli F, Marcelli D, Conte F, et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 2001; 12:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/33\">",
"      Fenton SS, Schaubel DE, Desmeules M, et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997; 30:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/34\">",
"      Johansen KL, Zhang R, Huang Y, et al. Survival and hospitalization among patients using nocturnal and short daily compared to conventional hemodialysis: a USRDS study. Kidney Int 2009; 76:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/35\">",
"      Schaubel DE, Morrison HI, Fenton SS. Comparing mortality rates on CAPD/CCPD and hemodialysis. The Canadian experience: fact or fiction? Perit Dial Int 1998; 18:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/36\">",
"      Collins AJ, Hao W, Xia H, et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999; 34:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/37\">",
"      Termorshuizen F, Korevaar JC, Dekker FW, et al. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol 2003; 14:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/38\">",
"      Heaf JG, L&oslash;kkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrol Dial Transplant 2002; 17:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/39\">",
"      Liem YS, Wong JB, Hunink MG, et al. Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. Kidney Int 2007; 71:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/40\">",
"      McDonald SP, Marshall MR, Johnson DW, Polkinghorne KR. Relationship between dialysis modality and mortality. J Am Soc Nephrol 2009; 20:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/41\">",
"      Foley RN, Parfrey PS, Harnett JD, et al. Mode of dialysis therapy and mortality in end-stage renal disease. J Am Soc Nephrol 1998; 9:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/42\">",
"      Yeates K, Zhu N, Vonesh E, et al. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. Nephrol Dial Transplant 2012; 27:3568.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009.",
"    </li>",
"    <li>",
"     U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/45\">",
"      Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004; 66:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/46\">",
"      H&eacute;bert MJ, Falardeau M, Pichette V, et al. Continuous ambulatory peritoneal dialysis for patients with severe left ventricular systolic dysfunction and end-stage renal disease. Am J Kidney Dis 1995; 25:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/47\">",
"      Stack AG, Molony DA, Rahman NS, et al. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int 2003; 64:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/48\">",
"      Ganesh SK, Hulbert-Shearon T, Port FK, et al. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol 2003; 14:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/49\">",
"      Xue JL, Everson SE, Constantini EG, et al. Peritoneal and hemodialysis: II. Mortality risk associated with initial patient characteristics. Kidney Int 2002; 61:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/50\">",
"      Jaar BG, Coresh J, Plantinga LC, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005; 143:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/51\">",
"      Weinhandl ED, Foley RN, Gilbertson DT, et al. Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J Am Soc Nephrol 2010; 21:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/52\">",
"      Nolph KD. Why are reported relative mortality risks for CAPD and HD so variable? (inadequacies of the Cox proportional hazards model). Perit Dial Int 1996; 16:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/53\">",
"      Ward RA, Brier ME. Retrospective analyses of large medical databases: what do they tell us? J Am Soc Nephrol 1999; 10:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/54\">",
"      Vale L, Cody J, Wallace S, et al. Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home haemodialysis for end-stage renal disease in adults. Cochrane Database Syst Rev 2003; :CD003963.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes. Bethesda, MD 2012.",
"    </li>",
"    <li>",
"     U.S. Renal Data System, USRDS 2007 Annual Data Report: Atlas of Chronic Kidney and End-Stage Renal Disease in the United States, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/57\">",
"      Schaubel DE, Blake PG, Fenton SS. Effect of renal center characteristics on mortality and technique failure on peritoneal dialysis. Kidney Int 2001; 60:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/58\">",
"      Dumler F, Stalla K, Mohini R, et al. Clinical experience with short-time hemodialysis. Am J Kidney Dis 1992; 19:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/59\">",
"      Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/60\">",
"      Chandran PK, Liggett R, Kirkpatrick B. Patient survival on PAN/AN69 membrane hemodialysis: a ten-year analysis. J Am Soc Nephrol 1993; 4:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/61\">",
"      Hakim RM, Held PJ, Stannard DC, et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996; 50:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/62\">",
"      Wolfe RA, Gaylin DS, Port FK, et al. Using USRDS generated mortality tables to compare local ESRD mortality rates to national rates. Kidney Int 1992; 42:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/63\">",
"      Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/64\">",
"      Cheung AK, Levin NW, Greene T, et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003; 14:3251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/65\">",
"      Chauveau P, Nguyen H, Combe C, et al. Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 2005; 45:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/66\">",
"      Palmer SC, Rabindranath KS, Craig JC, et al. High-flux versus low-flux membranes for end-stage kidney disease. Cochrane Database Syst Rev 2012; 9:CD005016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/67\">",
"      Mailloux LU, Bellucci AG, Wilkes BM, et al. Mortality in dialysis patients: analysis of the causes of death. Am J Kidney Dis 1991; 18:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/68\">",
"      Mailloux LU, Bellucci AG, Napolitano B, et al. Survival estimates for 683 patients starting dialysis from 1970 through 1989: identification of risk factors for survival. Clin Nephrol 1994; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34312/abstract/69\">",
"      Kramer P, Broyer M, Brunner FP, et al. Combined report on regular dialysis and transplantation in Europe, XII, 1981. Proc Eur Dial Transplant Assoc 1983; 19:4.",
"     </a>",
"    </li>",
"    <li>",
"     ERA-EDTA Registry: Annual Academic Medical Center. Amsterdam, The Netherlands, 2003.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1844 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-0D5B978519-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34312=[""].join("\n");
var outline_f33_32_34312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SELECTION OF DIALYSIS MODALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SURVIVAL BY MODALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Peritoneal dialysis versus in-center hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      High-flux and high-efficiency hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Home, nocturnal, and short-daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hemodialysis versus hemodiafiltration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PRETRANSPLANTATION DIALYSIS MODALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1844\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1844|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/40/43661\" title=\"figure 1\">",
"      HD survival by site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/21/1375\" title=\"figure 2\">",
"      5 year survival ESRD pts 2007 USRDS data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/35/10814\" title=\"figure 3\">",
"      Mortality ESRD pts 2007 USRDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/58/36781\" title=\"figure 4\">",
"      High and low flux HEMO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/39/30330?source=related_link\">",
"      Alternative renal replacement therapies in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31286?source=related_link\">",
"      Choosing a modality for chronic peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26902?source=related_link\">",
"      Clinical consequences of hemodialysis membrane biocompatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11224?source=related_link\">",
"      Dialysis issues prior to and after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19144?source=related_link\">",
"      Home hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/24/3465?source=related_link\">",
"      Outcomes associated with nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33530?source=related_link\">",
"      Sustained low efficiency or extended daily dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_32_34313="Phytophotodermatitis 1";
var content_f33_32_34313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77829%7EDERM%2F57871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77829%7EDERM%2F57871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phytophotodermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous linear streaks that subsequently became hyperpigmented occurred on the trunk of this 14-year-old male who was exposed to the sun after squeezing limes during a Carribean vacation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phytophotodermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After making lemonade during an outdoor excursion trip, this 38-year-old female presented with erythematous linear and angulated patches and crusts on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34313=[""].join("\n");
var outline_f33_32_34313=null;
var title_f33_32_34314="Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis";
var content_f33_32_34314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/32/34314/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/32/34314/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/32/34314/contributors\">",
"     Andre A Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/32/34314/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/32/34314/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/32/34314/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/32/34314/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/32/34314/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/32/34314/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1878722\">",
"    <span class=\"h1\">",
"     NEW TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In January 2011, the Boards of Directors of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism recommended that the name Wegener's granulomatosis be changed to granulomatosis with polyangiitis (Wegener's), abbreviated as GPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This change reflects a plan to gradually shift from honorific eponyms to a disease-descriptive or etiology-based nomenclature. The parenthetic reference to Wegener's will be phased out after several years as the new name becomes more widely known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener's), which can be abbreviated as GPA, and microscopic polyangiitis (MPA) are related systemic vasculitides. Both are associated with antineutrophil cytoplasmic antibodies (ANCA), have similar features on renal histology (eg, a focal necrotizing, pauci-immune glomerulonephritis), and have similar outcomes. There are, however, several differences between these disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link&amp;anchor=H11698538#H11698538\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy of GPA and MPA has two components: induction of remission with initial immunosuppressive therapy, and maintenance immunosuppressive therapy for a variable period to prevent relapse.",
"   </p>",
"   <p>",
"    The initial immunosuppressive therapy of GPA and MPA will be reviewed here. Maintenance immunosuppressive therapy following induction of remission, the treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    resistant or relapsing disease, the clinical manifestations and diagnosis of these disorders, and patient and renal outcomes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3321?source=see_link\">",
"     \"Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9130?source=see_link\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24824?source=see_link\">",
"     \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Assessment of disease activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of methods have been used to assess disease activity in patients with granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, or microscopic polyangiitis (MPA). As an example, the Birmingham Vasculitis Activity Score (BVAS) has been applied to patients with GPA",
"    <span class=\"nowrap\">",
"     (BVAS/GPA).",
"    </span>",
"    The score includes both general symptoms (arthralgia, arthritis, and fever) and involvement of eight major organ systems. At each site, persistent symptoms or manifestations (eg, hematuria) are given one point and new or worse symptoms are given two points. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28949?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the management of the vasculitides in adults\", section on 'Patient monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     BVAS/GPA",
"    </span>",
"    score ranges from 0 (complete remission) to a maximum of 68. Major manifestations are defined as those that pose an immediate threat to the patient's life or to the function of a vital organ. These include gangrene, alveolar hemorrhage, respiratory failure, nervous system involvement, sensorineural deafness, mesenteric ischemia, scleritis, retinal exudates or hemorrhage, red blood cell casts, and a rise in serum creatinine.",
"   </p>",
"   <p>",
"    Immunosuppressive therapy is indicated in all patients with active GPA or MPA. Even patients with advanced renal disease at presentation are highly likely to benefit. In one report, for example, remission was induced in 72 percent of 240 patients with an estimated glomerular filtration rate (eGFR) &le;30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    68 percent of 188 patients with an eGFR &le;20",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and 57 percent of 96 patients with an eGFR &le;10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Definition of complete remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction of complete remission is the goal of immunosuppressive therapy in GPA or MPA and is defined as the absence of active disease. A number of definitions of complete remission have been used and the definitions have evolved over time.",
"   </p>",
"   <p>",
"    In the 1992 National Institutes of Health study demonstrating the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , the criteria for complete remission included absence of systemic inflammatory disease such as serositis and fever, complete resolution of pulmonary infiltrates or stable scarring without signs of active inflammation, and an inactive urine sediment with stabilization of or improvement in renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar criteria were used in a 1996 report from the University of North Carolina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/6\">",
"     6",
"    </a>",
"    ]. Complete remission was defined as stabilization of or reduction in the serum creatinine and resolution of extrarenal manifestations. Persistent proteinuria was not considered a sign of persistent disease activity.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     BVAS/GPA",
"    </span>",
"    score described in the preceding section is more comprehensive, as it includes both systemic manifestations and involvement of eight organ systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Complete remission is defined as a score of 0. In terms of renal involvement, the",
"    <span class=\"nowrap\">",
"     BVAS/GPA",
"    </span>",
"    score uses hematuria or red cell casts as a sign of active disease. Red cell casts are not present in some patients with hematuria due to vasculitis and there can be many false positive and false negative results if read by inexperienced observers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Renal remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is no active renal inflammation, then hematuria and, if present, red cell casts should remit, which is defined as 0 to 3 red cells per high power field. However, there are two other potential causes of hematuria that can occur in patients with GPA or MPA that are unrelated to active renal inflammation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent hematuria at the time of apparent remission may reflect",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -induced cystitis. The red cells in this setting are typically isomorphic (normomorphic), not dysmorphic as with glomerular hematuria (",
"      <a class=\"graphic graphic_picture graphicRef79440 graphicRef62064 \" href=\"mobipreview.htm?40/13/41170\">",
"       picture 1A-B",
"      </a>",
"      ) and cystoscopy usually shows signs of bladder injury (70 percent in one series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H1824471562#H1824471562\">",
"       \"Etiology and evaluation of hematuria in adults\", section on 'Red cell morphology'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In addition, the hematuria due to bladder injury should resolve within three to four weeks after the last cyclophosphamide dose. Persistent monomorphic hematuria raises the possibility of cyclophosphamide-induced bladder cancer, which is not typically seen with the usually short duration of cyclophosphamide therapy now used in patients with GPA or MPA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link&amp;anchor=H25#H25\">",
"       \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Cyclophosphamide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Premenopausal women often have blood in the urine during menses due to contamination from menstrual bleeding. Short of bladder catheterization, the etiology of hematuria is best determined by repeat urinalysis after the cessation of menses. This is not a common issue in patients with GPA or MPA, since the mean age is over 50 years and most affected women are postmenopausal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Active disease versus irreversible injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete remission does NOT mean that all parameters have to return to baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/5\">",
"     5",
"    </a>",
"    ]. Many patients have persistent abnormalities that reflect irreversible injury induced during the period of active inflammation. As an example, a patient in whom systemic symptoms and signs resolve and the urinalysis becomes inactive (ie, no hematuria) is considered to be in remission, even if there is persistent proteinuria and persistent or even slowly worsening renal insufficiency. In addition, late progression of the renal disease can result from factors (eg, intraglomerular hypertension) that result from initial nephron loss rather than continuing disease activity. Angiotensin inhibition may be beneficial in such patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Partial remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial remission is more difficult to define. In the kidney, partial remission refers to the persistence of dysmorphic (ie, glomerular) hematuria with or without red blood cell casts despite improvement in or stabilization of the serum creatinine and disappearance of extrarenal signs of active disease (",
"    <a class=\"graphic graphic_picture graphicRef79440 graphicRef62064 \" href=\"mobipreview.htm?40/13/41170\">",
"     picture 1A-B",
"    </a>",
"    ). This is a smoldering process that can lead to progressive renal injury and usually indicates the need for further therapy. On the other hand, persistent proteinuria may reflect irreversible glomerular injury and, as an isolated finding, is not indicative of active disease.",
"   </p>",
"   <p>",
"    Dysmorphic hematuria must be distinguished from isomorphic hematuria, which is characteristic of extraglomerular bleeding and, in patients receiving initial immunosuppressive therapy, may reflect",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -induced bladder toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H1824471562#H1824471562\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Red cell morphology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smoldering disease in the respiratory tract is a common and difficult problem. Active vasculitis in the upper respiratory tract must be distinguished from scarring, which can progress in the absence of active disease, and infection. Similarly, a nodule in the lung may represent active vasculitis, a scar, or infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cyclophosphamide resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;True",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    resistance is uncommon in GPA and MPA and is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3321?source=see_link\">",
"     \"Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, a report from the University of North Carolina defined treatment resistance as one or both of the following despite immunosuppressive therapy for at least one month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A progressive decline in renal function (ie, increase in serum creatinine) with persistence of an active urine sediment",
"     </li>",
"     <li>",
"      Persistence or new appearance of any extrarenal manifestations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some patients, resistance is incorrectly diagnosed with persistent manifestations being due to inadequate dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or to inactive disease rather than ongoing inflammation.",
"   </p>",
"   <p>",
"    There are at least two disease manifestations that may be relatively unresponsive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (and to other systemic therapies), but are NOT considered to represent resistant disease: orbital pseudotumor (retrobulbar masses); and subglottic stenosis, which may reflect scar rather than ongoing inflammation, and may respond best to local therapies such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    injections and dilatation procedures (avoiding laser therapies). (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Management of upper airway involvement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cannot take cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients have a contraindication to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy or refuse such therapy because of concerns about fertility, hair loss, the risk of malignancy, or other issues.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is the drug of choice for such patients since, in two randomized trials, rituximab was as effective as cyclophosphamide in inducing remission among patients with newly diagnosed or relapsing GPA or MPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. A potential limitation is that the duration of follow-up was limited to six to twelve months compared with the extensive long-term experience with cyclophosphamide. (See",
"    <a class=\"local\" href=\"#H16198972\">",
"     'Rituximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INITIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, and MPA typically consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    may be used in patients who cannot, or refuse to take cyclophosphamide.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    may have a role in patients with mild disease, and selected patients with severe disease benefit from the addition of plasma exchange. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Role of plasma exchange'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of aggressive initial immunosuppression is justified because the mortality rate in untreated generalized GPA is as high as 90 percent at two years, usually due to respiratory or renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/5\">",
"     5",
"    </a>",
"    ]. Mortality has markedly diminished with the introduction of initial therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Choice of cyclophosphamide regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    dosing regimens, daily oral and monthly intravenous pulses, have been used for initial immunosuppressive therapy of GPA and MPA. Data from comparative trials have shown that the two regimens induce remission of active disease at a similar rate. Daily oral therapy has the advantage of a lower rate of relapse and the disadvantages of more leukopenia and possibly infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/12-17\">",
"     12-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both regimens are used clinically. This was illustrated in a community-based cohort study of 350 patients who received a new diagnosis of ANCA-associated vasculitis between 1985 and 2003 and were followed by physicians in the Glomerular Disease Collaborative Network [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/4\">",
"     4",
"    </a>",
"    ]. Among the patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    induction, 161 received monthly intravenous therapy and 112 received daily oral therapy. Patient preference may contribute to the choice of regimen once the advantages and disadvantages are described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Daily oral cyclophosphamide and glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians favor daily oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -glucocorticoid combination therapy in the initial treatment of patients with GPA or MPA. One of the largest nonrandomized, prospective single center studies reported the outcomes in 158 patients with GPA who were treated with varying regimens at the National Institutes of Health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/5\">",
"     5",
"    </a>",
"    ]. \"Standard\" low-dose cyclophosphamide plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , low-dose cyclophosphamide alone, non-cyclophosphamide cytotoxic agents plus steroids, or glucocorticoids alone were administered to 133, 8, 6, and 10 patients, respectively. Cyclophosphamide was administered for a mean of two years.",
"   </p>",
"   <p>",
"    The following outcomes were reported at a mean follow-up of eight years (range 6 months to 24 years):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survival was 80 percent, with most deaths being due to GPA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      side effects of therapy.",
"     </li>",
"     <li>",
"      Significant clinical improvement was observed in more than 90 percent of patients, with 75 percent achieving complete remission.",
"     </li>",
"     <li>",
"      Among the 98 patients followed for more than five years, almost one-half experienced remissions lasting more than five years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings have been noted in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/6,18-23\">",
"     6,18-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cyclophosphamide regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is given orally in a dose of 1.5 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Therapy is continued until a stable remission is induced, which is usually achieved within three to six months. The white blood cell count (WBC) should be closely monitored and the cyclophosphamide dose adjusted to avoid severe leukopenia. The WBC should remain above",
"    <span class=\"nowrap\">",
"     3000/microL",
"    </span>",
"    and the absolute neutrophil count above",
"    <span class=\"nowrap\">",
"     1500/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link&amp;anchor=H24#H24\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Glucocorticoid regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;When initiating glucocorticoid therapy, there is disagreement among experts and among the authors as to whether therapy should begin with pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (7 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    to a maximum dose of 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three days) in all patients or only in those with necrotizing or crescentic glomerulonephritis or more severe respiratory disease. Oral glucocorticoid therapy, either from day one or from day four if pulse methylprednisolone is given, typically consists of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum of 60 to 80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or its equivalent).",
"   </p>",
"   <p>",
"    A variety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    tapering schemes has been employed. In general, the initial dose is continued for two to four weeks. If significant improvement is observed at this time, the dose of prednisone is tapered slowly, with the goal of reaching 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by the end of two months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/18,24\">",
"     18,24",
"    </a>",
"    ]. Historically, the total duration of prednisone therapy has been six to nine months unless needed for control of persistent systemic symptoms. However, the use of glucocorticoids beyond six months is associated with a significantly higher incidence of infections but is",
"    <strong>",
"     not",
"    </strong>",
"    associated with a reduced risk of relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, unless required for resistant disease, we suggest tapering glucocorticoids by six months. Alternate day glucocorticoid regimens, once recommended in GPA, are",
"    <strong>",
"     not",
"    </strong>",
"    generally employed now.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Rate and time to remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids induces remission in 85 to 90 percent of patients, with approximately 75 percent experiencing complete remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/5,6,12,13,18-23\">",
"     5,6,12,13,18-23",
"    </a>",
"    ]. Most remissions occur between two and six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/12,23\">",
"     12,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Definition of complete remission'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Reasonable estimates of the rate and time to remission with common treatment regimens were provided by CYCAZAREM (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     CYClophosphamide",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     AZAthioprine",
"    </a>",
"    for the maintenance of REMission), a trial of 155 patients with ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/23\">",
"     23",
"    </a>",
"    ], and WGET (Wegener's Granulomatosis",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    Trial), a trial of 180 patients with GPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In CYCAZAREM, 93 percent of patients achieved remission: 77 percent within three months, and an additional 16 percent between three and six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In WGET, 91 percent achieved disease remission and 73 percent had a sustained complete remission lasting at least six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relapses occurred after the induction of remission in both trials, although the rates were different: approximately 15 percent at 18 months in CYCAZAREM and approximately 50 percent at 27 months in WGET. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9130?source=see_link\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Persistent disease-related morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the NIH study cited above, 86 percent of patients had clinically important morbidity from the disease at a mean follow-up of eight years despite adequate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/5\">",
"     5",
"    </a>",
"    ]. Common extrarenal complications included hearing loss (35 percent), cosmetic and functional nasal deformities (28 percent), and tracheal stenosis (13 percent). In addition, 42 percent of patients had chronic kidney disease, with a median serum creatinine concentration of 2.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (229",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at an average follow-up of seven to eight years. As expected, segmental sclerosis of previously active glomerular lesions was the most common finding on renal biopsy. Eleven percent progressed to end-stage renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24824?source=see_link\">",
"     \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Monthly intravenous cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monthly intravenous pulses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    have been evaluated in GPA and MPA in an attempt to lower the overall cumulative dose of cyclophosphamide. Randomized trials comparing the two approaches have shown that the rate of induction of remission with monthly intravenous cyclophosphamide compared to daily oral therapy is equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. In almost all of these studies, monthly intravenous therapy had the advantages of lower total cyclophosphamide exposure and a lower rate of neutropenia and infection, but a higher rate of relapse.",
"   </p>",
"   <p>",
"    The best data come from a randomized trial of 149 patients with ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/12\">",
"     12",
"    </a>",
"    ], after which long-term follow-up data (median 4.3 years) were ascertained retrospectively on 134 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/17\">",
"     17",
"    </a>",
"    ]. During the trial, patients were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    and either pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two to three weeks) or daily oral cyclophosphamide (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). The primary outcome was the time to remission and secondary outcomes included the relapse rate, change in renal function, adverse events, and cumulative dose of cyclophosphamide.",
"   </p>",
"   <p>",
"    The following findings were noted during the trial phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference in the time to remission or the percentage of patients who achieved remission by nine months (88 percent in both groups). Most remissions occurred between two and six months.",
"     </li>",
"     <li>",
"      The mean estimated glomerular filtration rate improved by a similar amount in both groups from about 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 at study entry to 45",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 at study end.",
"     </li>",
"     <li>",
"      Among the patients who achieved remission by nine months, 19 (14.5 percent) relapsed (10 major and 9 minor). There were more relapses in the intravenous pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      group (13 versus 6), a difference that was not statistically significant but the study was not designed or powered to assess an effect on relapse.",
"     </li>",
"     <li>",
"      Pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      compared to daily oral cyclophosphamide was associated with a significantly lower cumulative cyclophosphamide dose (8.2 versus 15.8 g) and a lower rate of leukopenia (26 versus 45 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During a median of 4.3 years of follow-up, the following findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference in the number of deaths (13 in the intravenous pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      group and 12 in the daily oral group).",
"     </li>",
"     <li>",
"      Significantly more patients in the intravenous pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      group had at least one relapse (40 versus 21 percent). The total number of relapses was significantly greater with intravenous pulse cyclophosphamide (54 versus 21 relapses).",
"     </li>",
"     <li>",
"      Despite the higher relapse rate, there was no difference in the incidence of end-stage renal disease (13 versus 11 percent), and the median serum creatinine in the two groups at last follow-up was identical (1.32",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [117",
"      <span class=\"nowrap\">",
"       micromol/L]).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results are consistent with a prior meta-analysis that included 143 patients from three small randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/16\">",
"     16",
"    </a>",
"    ]. Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    was at least as effective as oral cyclophosphamide for inducing remission and was associated with a significantly lower rate of leukopenia and infection and a trend toward a higher rate of relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Alternative regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the toxicity associated with the prolonged administration of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , several alternative regimens have been evaluated for initial therapy. None has supplanted the oral cyclophosphamide-glucocorticoid regimen, although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is the preferred therapy for patients who cannot take or refuse cyclophosphamide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16198972\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials have suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may be an effective alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for the initial treatment of patients who have newly diagnosed disease or have relapsed following treatment with cyclophosphamide or other immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter noninferiority trial (the RAVE trial) compared induction therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per week for four weeks) or with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) in 197 patients with GPA (75 percent of enrolled patients) or MPA (24 percent); 49 percent of patients were newly diagnosed and the remainder had relapsing disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/11\">",
"       11",
"      </a>",
"      ]. All patients received one to three pulses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1000 mg) followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day). Rituximab was noninferior to cyclophosphamide in inducing remission by six months (64 versus 53 percent). However, in the 100 patients with relapsing disease, rituximab was superior to cyclophosphamide in inducing remission (67 versus 42 percent). There was no difference in the number of adverse events.",
"     </li>",
"     <li>",
"      In the second trial (RITUXVAS), 44 patients with newly diagnosed ANCA-associated renal vasculitis were assigned in a 3:1 ratio to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1000 mg) followed by oral methylprednisolone (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day with reduction to 5 mg per day by the end of six months) plus either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per week for four weeks) with two intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      pulses (15",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      or intravenous cyclophosphamide for three to six months followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/10\">",
"       10",
"      </a>",
"      ]. Patients who received rituximab who had progressive disease within the first six months were given a third dose of cyclophosphamide (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day). At 12 months, there was no difference in the rate of sustained remission (defined as the absence of disease activity for at least six months) between the rituximab and cyclophosphamide only groups (76 versus 82 percent). There was also no difference between groups in the rate of adverse events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for the initial treatment of GPA and MPA or for patients with relapsing disease. However, both studies are limited in the duration of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/26\">",
"     26",
"    </a>",
"    ]. Until such data are available, we prefer cyclophosphamide to rituximab as initial therapy for GPA and MPA. However, rituximab is the preferred therapy for patients who cannot take or refuse cyclophosphamide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-dose weekly oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    has been used as initial therapy in patients with GPA who have non-organ threatening and non-life threatening disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/24,27-31\">",
"     24,27-31",
"    </a>",
"    ] and, as discussed elsewhere, as maintenance therapy in patients treated initially with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or methotrexate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=see_link&amp;anchor=H5#H5\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best data on the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    come from the randomized NORAM trial that compared methotrexate and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for both induction and remission of ANCA-associated vasculitis without significant renal involvement (mean serum creatinine 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (85",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and microscopic hematuria in only 28 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/29\">",
"     29",
"    </a>",
"    ]. The trial enrolled 89 patients with newly diagnosed GPA and 6 with MPA, all of whom had \"early generalized disease.\" The exclusion criteria were signs of potentially severe systemic disease as manifested by a serum creatinine greater than 1.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (150",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    red blood cell casts, severe hemoptysis, cerebral infarction due to vasculitis, orbital pseudotumor, or rapidly progressive neuropathy.",
"   </p>",
"   <p>",
"    The patients were assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (20 to 25 mg per week orally) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally); all received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    . Therapy was gradually tapered and withdrawn by 12 months.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At six months, 90 and 94 percent of patients in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      arms, respectively, achieved remission, although time to remission was two months longer in the methotrexate group.",
"     </li>",
"     <li>",
"      Among the patients who achieved remission, the relapse rate at 18 months was significantly higher with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (70 versus 47 percent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In terms of adverse outcomes, there was a higher incidence of leukopenia among those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and a higher incidence of liver function test abnormalities among those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      . Two patients in each group died.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    was as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for the induction of remission in patients with mild disease, but was associated with a significantly higher relapse rate. The 2008 European League Against Rheumatism (EULAR) guidelines recommended the combination of oral or parenteral methotrexate and glucocorticoids as a less toxic alternative than cyclophosphamide for induction of remission in non-organ threatening and non-life threatening ANCA associated vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/31\">",
"     31",
"    </a>",
"    ]. Rheumatologists have the most experience with methotrexate for induction therapy, while most nephrologists have little or no experience with this approach.",
"   </p>",
"   <p>",
"    Given the higher relapse rate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    should probably be used primarily for limited disease not involving the kidney. It may also be used in selected patients who do not tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . Given the risk of toxicity in patients with renal dysfunction, methotrexate should",
"    <strong>",
"     not",
"    </strong>",
"    be used when the estimated glomerular filtration rate is below 50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Glucocorticoids alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid monotherapy is NOT generally considered for remission induction, since the reported remission rate is much lower than in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (56 versus 85 percent), and the rate of relapse much higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/6\">",
"     6",
"    </a>",
"    ]. This is particularly true for patients with severe disease manifestations, such as glomerulonephritis. Among 57 patients evaluated at the National Institutes of Health who were initially treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone, none of those with renal disease (45 patients) experienced sustained improvement, and 55 of the 57 (96 percent) eventually required cytotoxic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Role of plasma exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several controlled trials of patients with GPA, MPA, or the related disorder segmental necrotizing glomerulonephritis with no immune deposits on pathologic examination (which is thought to represent renal-limited vasculitis) have demonstrated no overall benefit for the renal disease from plasma exchange, with the possible exception of patients who one or more of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/20,33-39\">",
"     20,33-39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe renal disease, which has been variably defined",
"     </li>",
"     <li>",
"      Concurrent anti-glomerular basement membrane (GBM) antibody disease",
"     </li>",
"     <li>",
"      Severe pulmonary hemorrhage",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Severe active renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two trials have evaluated the efficacy of plasma exchange in patients with GPA or MPA who have severe active renal disease. Potential efficacy of plasma exchange was evaluated in an initial randomized trial in which 48 patients with focal necrotizing glomerulonephritis were assigned to immunosuppressive therapy with or without plasma exchange; pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    was not given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/33\">",
"     33",
"    </a>",
"    ]. There was no difference in outcome among the 17 patients with a serum creatinine concentration of less than 5.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (500",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or the 12 with higher serum creatinine concentrations in whom dialysis was not required. In contrast, plasma exchange appeared to be of benefit in the patients who required dialysis.",
"   </p>",
"   <p>",
"    The role of plasma exchange in patients with severe renal disease was also addressed in the randomized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     Methylprednisolone",
"    </a>",
"    versus Plasma Exchange (MEPEX) trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/39\">",
"     39",
"    </a>",
"    ]. This trial enrolled 137 patients with a new diagnosis of GPA or MPA, pauci-immune glomerulonephritis, and a serum creatinine concentration above 5.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (500",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    The mean serum creatinine at presentation was 8.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (735",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and 69 percent required dialysis, which, in the preceding trial, identified patients who benefited from plasma exchange.",
"   </p>",
"   <p>",
"    The patients were assigned randomly to receive either seven sessions of plasma exchange over the first two weeks after diagnosis or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    for three days. In addition to these therapies, patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, tapered over six months) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three months), followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    for remission maintenance.",
"   </p>",
"   <p>",
"    The major results of the MEPEX trial are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma exchange was associated with a significantly higher likelihood of being alive and having independent renal function at three months (69 versus 49 percent in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      group).",
"     </li>",
"     <li>",
"      Plasma exchange was associated with a significant reduction in the risk of progression to end-stage renal disease at one year (19 versus 43 percent).",
"     </li>",
"     <li>",
"      The mortality rate was high in both groups (27 and 24 percent at one year). The majority of deaths occurred in the first three months of treatment. Of the 35 deaths in the trial, 19 were related to infection, 6 to pulmonary hemorrhage, and 4 to cardiovascular events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The MEPEX trial had a number of important shortcomings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The trial was not blinded and was not optimally designed. A preferable trial design would have provided pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      to both treatment groups at the outset of therapy and then randomly assigned patients to either plasma exchange or sham plasma exchange.",
"     </li>",
"     <li>",
"      The plasma exchange regimens varied significantly from site to site.",
"     </li>",
"     <li>",
"      The mortality rate at one year appears excessive compared to other trials, even allowing for the fact that patients in MEPEX had more severe renal disease at baseline than in other trials. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24824?source=see_link&amp;anchor=H4#H4\">",
"       \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Mortality'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these limitations, the results of the MEPEX trial support the notion that the addition of plasma exchange to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoid therapy may enhance the recovery of renal function among patients who present with severe renal dysfunction (serum creatinine above 5.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (500",
"    <span class=\"nowrap\">",
"     micromol/L))",
"    </span>",
"    during the acute phase of disease.",
"   </p>",
"   <p>",
"    In a meta-analysis of nine trials (of which the MEPEX was by far the largest) and including 387 patients, the addition of plasma exchange to standard care decreased the pooled risk of end-stage renal disease or death (RR 0.8, 95% CI, 0.65-0.99) and of end-stage renal disease alone (RR 0.64, 95% CI 0.47-0.88) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/40\">",
"     40",
"    </a>",
"    ]. The serum creatinine of participants ranged from 3.2 to 13.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (283 to 1193",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    However, although these results were statistically significant, the calculated optimal information size (sample size) required to be confident of a risk reduction of roughly 25 percent is 1478 patients. Thus, reliable conclusions cannot be drawn from this underpowered analysis, although it supports the role of plasma exchange as a promising adjunctive therapy.",
"   </p>",
"   <p>",
"    For patients with advanced renal dysfunction without concurrent anti-GBM antibody disease, we suggest seven sessions of plasma exchange over two weeks (60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    at each session). Albumin is the preferred replacement fluid in patients without bleeding or a recent renal biopsy. For patients with bleeding or a recent biopsy, we suggest that one to two liters of fresh frozen plasma should be substituted for albumin at the end of the procedure to reverse pheresis-induced depletion of coagulation factors.",
"   </p>",
"   <p>",
"    Among patients who develop severe infection in the setting of plasma exchange, a single infusion of intravenous immune globulin (100 to 400",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    can be given to partially replenish antibody levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Concurrent anti-GBM antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based entirely upon presumed benefits in patients with anti-GBM antibody disease alone, plasma exchange is usually used in combination with immunosuppressive therapy in patients with ANCA-associated vasculitis who also have anti-GBM antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/16/7432?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of anti-GBM antibody (Goodpasture's) disease\", section on 'Plasmapheresis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Anti-GBM antibody disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Pulmonary hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although randomized controlled trials have not been performed, patients with pulmonary hemorrhage should be treated with plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. This strategy is based upon the theoretical benefit of removing ANCA by plasma exchange and the observed efficacy of plasma exchange in patients with pulmonary hemorrhage due to anti-GBM antibody disease.",
"   </p>",
"   <p>",
"    Benefits from plasma exchange in this setting were suggested in a retrospective review of 20 patients who presented between 1995 and 2001 with diffuse alveolar hemorrhage (DAH) and ANCA-associated small vessel vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/43\">",
"     43",
"    </a>",
"    ]. Fourteen of the patients presented with impaired renal function, with the average serum creatinine concentration being 4.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (415",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    All patients underwent daily full plasma volume plasma exchange until DAH improved, which was then changed to alternative day apheresis therapy until the DAH resolved. The replacement fluid was 5 percent albumin and two units of fresh frozen plasma at the end of apheresis. All patients also received intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for three days, and all but two received intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (0.5",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    of body surface area). Additional therapy included ventilatory support and hemodialysis for nine and seven patients, respectively.",
"   </p>",
"   <p>",
"    DAH resolved in all 20 patients, with the mean number of apheresis treatments being 6.15 (range of 4 to 9). There were no complications due to apheresis. One patient died because of a pulmonary embolism. Among the seven patients who did not require dialysis, the serum creatinine fell significantly by the time of discharge (4.5 to 2.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (398 to 212",
"    <span class=\"nowrap\">",
"     micromol/L)).",
"    </span>",
"   </p>",
"   <p>",
"    The results of this study must be interpreted in light of its retrospective design and lack of a control group. In addition, because all patients in the review received conventional therapies (generally",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids) in addition to plasma exchange, independent effects of plasma exchange are impossible to delineate.",
"   </p>",
"   <p>",
"    For patients with pulmonary hemorrhage, we suggest seven sessions of plasma exchange over two weeks (60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    at each session). Fresh frozen plasma is the preferred replacement fluid, with one to two liters being given at the end of the procedure to reverse pheresis-induced depletion of coagulation factors.",
"   </p>",
"   <p>",
"    Among patients who develop severe infection in the setting of plasma exchange, a single infusion of intravenous immune globulin (100 to 400",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    can be given to partially replenish antibody levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment-associated toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus glucocorticoid regimen is associated with important toxicity and does not reverse tissue necrosis. In addition to the toxicities discussed below, cytotoxic agents are toxic to the fetus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=see_link\">",
"     \"Pregnancy in women with underlying renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the 1992 NIH study cited above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy resulted in a 57 percent incidence of either amenorrhea lasting more than one year or inability to become pregnant; gonadal function in men was not evaluated. Other reported toxicities included cystitis (50 percent), bladder cancer (5.6 percent), myelodysplasia (2 percent), and lymphoma (0.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/5\">",
"     5",
"    </a>",
"    ]. A detailed discussion of the measures available to minimize toxicity associated with this regimen can be found in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reported toxicities of extended glucocorticoid therapy in the NIH study were cataracts (21 percent), diabetes mellitus (8 percent), osteopenia, fractures (11 percent), and aseptic necrosis of bone (3 percent). In addition, severe gastritis may develop and result in gastrointestinal bleeding in patients at increased risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     PCP prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis carinii (jiroveci) pneumonia (PCP) and other opportunistic infections are potentially fatal complications of immunosuppressive therapy in GPA or MPA. In one series, for example, PCP developed in 11 of 180 (6 percent) patients with GPA, all of whom were treated with daily glucocorticoids and a second immunosuppressive drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylaxis may be both cost-saving and life-prolonging in this setting. We administer prophylaxis during induction therapy; the suggested regimen varies with the regimen used for initial immunosuppression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and glucocorticoids, we use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (one single strength (80",
"      <span class=\"nowrap\">",
"       mg/400",
"      </span>",
"      mg) tablet daily or one double strength tablet (160",
"      <span class=\"nowrap\">",
"       mg/800",
"      </span>",
"      mg) three times per week).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"       Atovaquone",
"      </a>",
"      is preferred in patients who are allergic to sulfonamides or do not tolerate trimethoprim-sulfamethoxazole.",
"     </li>",
"     <li>",
"      For patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and glucocorticoids, the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      is associated with an increased risk of pancytopenia.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"       Atovaquone",
"      </a>",
"      may be used for prophylaxis in such patients.",
"     </li>",
"     <li>",
"      After",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      is discontinued and maintenance immunosuppressive therapy is initiated, we continue PCP prophylaxis until the CD4-positive T cell count exceeds",
"      <span class=\"nowrap\">",
"       300/microL.",
"      </span>",
"      This empiric threshold is derived from that used for HIV-infected patients",
"      <span class=\"nowrap\">",
"       (200/microL)",
"      </span>",
"      with an extra margin for safety since patients with ANCA-associated vasculitis have more severe disease and higher mortality rates with PCP than HIV-infected patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Outcomes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients who have been treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    for prophylaxis during induction, we continue trimethoprim-sulfamethoxazole when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is used for maintenance therapy and switch to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is used for maintenance therapy.",
"   </p>",
"   <p>",
"    Some patients have low CD4-positive T cell counts for prolonged periods after the cessation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and require prolonged PCP prophylaxis, with glucocorticoids being tapered to the lowest possible dose. If patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    develop neutropenia, which is a possible side effect, we switch to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF UPPER AIRWAY INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequences of upper airway involvement are often not improved by initial immunosuppressive therapy and are NOT considered resistant disease.",
"   </p>",
"   <p>",
"    Nasal ulcers and crusting are common manifestations of upper airway disease in ANCA-associated vasculitis, particularly in GPA. It is often difficult to determine if these lesions are attributable to vasculitis, infection, or both. Although oral antibiotics are frequently required to treat more severe infections in the upper respiratory tract, some experts prefer a trial of topical therapy for nasal ulcers and crusting. This approach may involve either direct application of antibiotic ointment just inside of the nares",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nasal irrigation with a saline solution to which topical antibiotics have been added. Nasal saline sprays are available over the counter or may be made up as one quart of water with one teaspoon of brine or pickling salt and one teaspoon of baking soda.",
"   </p>",
"   <p>",
"    Lesions of the tracheobronchial tree can cause a variety of problems. The most serious complications include tracheal or bronchial stenosis that can lead to respiratory failure or postobstructive pneumonia. Treatment options for these problems include airway dilation with or without stenting. For subglottic stenosis, intralesional injection of glucocorticoids in combination with endoscopic dilation may avoid the need for more invasive surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tracheostomy should be avoided whenever possible. When tracheostomy is necessary, most patients are able to have the tracheostomy tube removed. This was illustrated in a retrospective report of 27 patients with ANCA-associated vasculitis: 11 required tracheostomy and 3 could not be decannulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stenosing lesions of the nasal passages and destructive lesions of the nasal cartilage and bones may cause discomfort",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    be disfiguring. Reconstructive surgery may provide a functional airway and can restore a more nearly normal appearing nose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/49\">",
"     49",
"    </a>",
"    ]. Grafts prepared from a patient's costal or auricular cartilage, iliac or other bone, or dura have been used with varying success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MANAGEMENT IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is only limited information on pregnancy complicated by GPA or MPA, although both newly diagnosed and relapsing GPA can occur during pregnancy or in the postpartum period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/32/34314/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. As with active disease in nonpregnant patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone is relatively ineffective, particularly for moderate to severe disease, while remission can be induced by combined therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The major challenges in treating active disease during pregnancy are that potentially serious adverse effects can occur with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and with alternative therapies such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    . In addition, there are insufficient data to assess the safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , (which has been used for non-pregnant patients who cannot tolerate cyclophosphamide) in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3321?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Mycophenolate mofetil'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H23#H23\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    exposure during the first trimester has been associated with a high risk of skeletal and palatal defects, as well as malformations of the limbs and eyes. The fetal risk is much smaller with cyclophosphamide therapy during the second and third trimesters, but pancytopenia and impaired fetal growth can occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H15#H15\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Cyclophosphamide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link&amp;anchor=H13#H13\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Teratogenicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) increases the risk of miscarriage and congenital malformation such as cleft lip and palate. As a result, MMF has a boxed warning for these complications and some consider MMF to be contraindicated in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H18#H18\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, there are three major therapeutic approaches in women with significant active disease during pregnancy: the use of safer immunosuppressive drugs; therapeutic abortion prior to initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based therapy, and the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , which has insufficient safety data for use in pregnancy.",
"   </p>",
"   <p>",
"    The safer immunosuppressive drugs that have been effective in GPA and MPA include glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ), particularly in mild to moderate disease. These drugs can also be tried for severe disease. Alternatives that could be considered include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in the second or third trimester once organogenesis is complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once remission is induced with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy (which usually occurs within three to six months), patients are switched to maintenance therapy with less toxic immunosuppressive drugs, usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/15/27889?source=see_link\">",
"       \"Patient information: Granulomatosis with polyangiitis (Wegener&rsquo;s) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener's), which can be abbreviated as GPA, and microscopic polyangiitis (MPA) are related systemic vasculitides that are associated with antineutrophil cytoplasmic antibodies (ANCA). GPA and MPA have similar features on renal histology and similar outcomes. Therapy of GPA and MPA has two components: the induction of remission; and maintenance immunosuppressive therapy to prevent relapse. Induction of complete remission, defined as the absence of active disease, is the goal of initial immunosuppressive therapy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Definition of complete remission'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1653370\">",
"    <span class=\"h2\">",
"     Cyclophosphamide or rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids, which is preferred in the great majority of patients, induces remission in 85 to 90 percent of patients, usually with two to six months. Two randomized trials have suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may be an effective alternative to cyclophosphamide for the initial treatment of patients who have newly diagnosed disease but both studies are limited in the duration of follow-up. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Rate and time to remission'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16198972\">",
"     'Rituximab'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients with newly diagnosed organ-threatening or life-threatening disease, we recommend initial immunosuppressive therapy with glucocorticoids plus either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (either oral or intravenous) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      rather than other therapies or glucocorticoids alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Until long-term data on the effectiveness and safety of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      are available, for patients with newly diagnosed organ-threatening or life-threatening disease who do not have a contraindication to, and do not refuse to take",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , we suggest initial immunosuppressive therapy with the combination of cyclophosphamide (either oral or intravenous) and glucocorticoids rather than rituximab and glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      There are two cyclophosphamide regimens: daily oral and monthly intravenous. Data from comparative trials have shown that the two regimens induce remission of active disease at a similar rate. Daily oral therapy has the advantage of a lower rate of relapse and the disadvantages are more leukopenia and possibly infection. Patient preference may contribute to the choice of regimen once the advantages and disadvantages are described. Regardless of the regimen chosen, close follow-up and monitoring for the development of neutropenia are indicated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choice of cyclophosphamide regimen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      is given, the preferred dose is 1.5 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Therapy is continued until a stable remission is induced, which is usually achieved within three to six months. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Daily oral cyclophosphamide and glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If pulse intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      is given, the preferred regimen is 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       g/m2",
"      </span>",
"      body surface area monthly for three to six months, until a stable remission is induced. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Monthly intravenous cyclophosphamide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , the white blood cell count (WBC) should be closely monitored and the cyclophosphamide dose adjusted to avoid severe leukopenia. The WBC should remain above",
"      <span class=\"nowrap\">",
"       3000/microL",
"      </span>",
"      and absolute neutrophil count above",
"      <span class=\"nowrap\">",
"       1500/microL.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link&amp;anchor=H24#H24\">",
"       \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Monitoring'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients with organ-threatening or life-threatening disease who cannot or refuse to take",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , we recommend initial immunosuppressive therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and glucocorticoids rather than other therapies (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cannot take cyclophosphamide'",
"      </a>",
"      above.) The preferred regimen is that used in the RAVE trial:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      375",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per week for four weeks given with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1000 mg) followed by oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. (See",
"      <a class=\"local\" href=\"#H16198972\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Glucocorticoid therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend glucocorticoid therapy in all patients with active GPA or MPA (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The decision to initiate glucocorticoids with intravenous pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      depends upon the severity of the disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Glucocorticoid regimen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with necrotizing or crescentic glomerulonephritis or severe respiratory disease, we suggest pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      followed by oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or its equivalent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The preferred regimen is 7 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      to a maximum dose of 500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for three days followed by oral prednisone on day four at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum of 60 to 80",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"     </li>",
"     <li>",
"      For patients who do not have necrotizing glomerulonephritis or severe respiratory disease, we suggest oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or its equivalent rather than initial pulse intravenous therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A suggested dose is 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum of 60 to 80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      beginning on day one. However, some clinicians prefer pulse",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      for three days in such patients.",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      or its equivalent is continued at the initial dose for two to four weeks. If significant improvement is observed at this time, the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is tapered slowly, with the goal of reaching 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      by the end of two months and an overall glucocorticoid course of six months. We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using alternate day glucocorticoid regimens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Methotrexate therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      given with glucocorticoid therapy is an alternative to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      for highly selected patients with non-organ-threatening and non-life-threatening disease such as those with pulmonary nodules or infiltrates without respiratory compromise,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ocular disease. Methotrexate should NOT be given to patients with an estimated glomerular filtration rate less than 50",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A suggested regimen is oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      at an initial dose of 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (but not exceeding 15 mg) once per week, with increases of 2.5 mg each week to a maximum dose of 25 mg once per week. Since methotrexate is a structural analogue of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      that can competitively inhibit the binding of dihydrofolic acid (FH2) to the enzyme dihydrofolate reductase (DHFR), folic acid (1 to 2",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or folinic acid (2.5 to 5 mg per week, 24 hours after methotrexate) should be given concurrently to reduce potential toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Plasma exchange",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of plasma exchange to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and glucocorticoid therapy may enhance the recovery of renal function among patients who present with severe renal dysfunction during the acute phase of disease. We suggest plasma exchange for patients with GPA or MPA who have anti-GBM antibodies as well as ANCA; for patients with severe pulmonary hemorrhage on presentation or those with worsening pulmonary hemorrhage despite the combination of high-dose glucocorticoids and cyclophosphamide; and for patients who have advanced renal dysfunction at presentation, as defined by a serum creatinine level above 5.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (500",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dialysis dependence (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Role of plasma exchange'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with advanced renal dysfunction, we suggest seven sessions of plasma exchange over two weeks (60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      at each session). A more intensive regimen is used in patients with anti-GBM disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/16/7432?source=see_link\">",
"       \"Treatment of anti-GBM antibody (Goodpasture's) disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients who have had a recent renal biopsy or have pulmonary hemorrhage, we suggest that one to two liters of fresh frozen plasma should be substituted for albumin at the end of the procedure to reverse pheresis-induced depletion of coagulation factors. For patient who have no evidence of hemorrhage or who are not at risk for bleeding, we suggest that albumin be used as the replacement fluid.",
"     </li>",
"     <li>",
"      Among patients who develop severe infection in the setting of plasma exchange, a single infusion of intravenous immune globulin (100 to 400",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      can be given to partially replenish antibody levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Role of PCP prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis carinii (jiroveci) pneumonia (PCP) and other opportunistic infections are potentially fatal complications of immunosuppressive therapy in GPA. The estimated incidence of PCP is approximately 6 percent. The suggested approach to prophylaxis against PCP infection during initial immunosuppressive therapy is discussed above. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'PCP prophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/1\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/2\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol 2011; 22:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/3\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis 2011; 70:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/4\">",
"      Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/5\">",
"      Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/6\">",
"      Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/7\">",
"      Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/8\">",
"      Mahr AD, Neogi T, Lavalley MP, et al. Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. Arthritis Rheum 2008; 59:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/9\">",
"      Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/10\">",
"      Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/11\">",
"      Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/12\">",
"      de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/13\">",
"      Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997; 90:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/14\">",
"      Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/15\">",
"      Haubitz M, Schellong S, G&ouml;bel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998; 41:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/16\">",
"      de Groot K, Adu D, Savage CO, EUVAS (European vasculitis study group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/17\">",
"      Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/18\">",
"      Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/19\">",
"      Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/20\">",
"      Glassock RJ. Intensive plasma exchange in crescentic glomerulonephritis: help or no help? Am J Kidney Dis 1992; 20:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/21\">",
"      Guillevin L, Lhote F. Treatment of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1998; 41:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/22\">",
"      Andrassy K, Erb A, Koderisch J, et al. Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol 1991; 35:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/23\">",
"      Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/24\">",
"      Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/25\">",
"      McGregor JG, Hogan SL, Hu Y, et al. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 2012; 7:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/26\">",
"      Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. N Engl J Med 2010; 363:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/27\">",
"      Sneller MC, Hoffman GS, Talar-Williams C, et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/28\">",
"      Specks U. Methotrexate for Wegener's granulomatosis: what is the evidence? Arthritis Rheum 2005; 52:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/29\">",
"      De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/30\">",
"      Villa-Forte A, Clark TM, Gomes M, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore) 2007; 86:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/31\">",
"      Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/32\">",
"      Hoffman GS. Wegener's granulomatosis. Curr Opin Rheumatol 1993; 5:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/33\">",
"      Pusey CD, Rees AJ, Evans DJ, et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/34\">",
"      Cole E, Cattran D, Magil A, et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 1992; 20:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/35\">",
"      Z&auml;uner I, Bach D, Braun N, et al. Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis 2002; 39:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/36\">",
"      Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/37\">",
"      Kaplan AA. The use of apheresis in immune renal disorders. Ther Apher Dial 2003; 7:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/38\">",
"      Buhaescu I, Covic A, Levy J. Systemic vasculitis: still a challenging disease. Am J Kidney Dis 2005; 46:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/39\">",
"      Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/40\">",
"      Walsh M, Catapano F, Szpirt W, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 2011; 57:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/41\">",
"      Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004; 66:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/42\">",
"      Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis 2002; 39:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/43\">",
"      Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/44\">",
"      Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995; 151:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/45\">",
"      Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000; 118:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/46\">",
"      Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis. Arthritis Rheum 1996; 39:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/47\">",
"      Hoffman GS, Thomas-Golbanov CK, Chan J, et al. Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol 2003; 30:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/48\">",
"      Gluth MB, Shinners PA, Kasperbauer JL. Subglottic stenosis associated with Wegener's granulomatosis. Laryngoscope 2003; 113:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/49\">",
"      Congdon D, Sherris DA, Specks U, McDonald T. Long-term follow-up of repair of external nasal deformities in patients with Wegener's granulomatosis. Laryngoscope 2002; 112:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/50\">",
"      Habib A, MacKay K, Abrons HL. Wegener's granulomatosis complicating pregnancy: presentation of two patients and review of the literature. Clin Nephrol 1996; 46:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/32/34314/abstract/51\">",
"      Langford CA, Kerr GS. Pregnancy in vasculitis. Curr Opin Rheumatol 2002; 14:36.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3105 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34314=[""].join("\n");
var outline_f33_32_34314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1878722\">",
"      NEW TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Assessment of disease activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Definition of complete remission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Renal remission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Active disease versus irreversible injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Partial remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cyclophosphamide resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cannot take cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Choice of cyclophosphamide regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Daily oral cyclophosphamide and glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cyclophosphamide regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Glucocorticoid regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Rate and time to remission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Persistent disease-related morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Monthly intravenous cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Alternative regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16198972\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Glucocorticoids alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Role of plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Severe active renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Concurrent anti-GBM antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Pulmonary hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment-associated toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - PCP prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MANAGEMENT OF UPPER AIRWAY INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MANAGEMENT IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1653370\">",
"      Cyclophosphamide or rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Methotrexate therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Role of PCP prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3105\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3105|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/0/24591\" title=\"picture 1A\">",
"      Phase contrast micrograph showing dysmorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/47/14079\" title=\"picture 1B\">",
"      Scanning electron micrograph showing dysmorphic red cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28949?source=related_link\">",
"      Overview of the management of the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24824?source=related_link\">",
"      Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/15/27889?source=related_link\">",
"      Patient information: Granulomatosis with polyangiitis (Wegener&rsquo;s) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9130?source=related_link\">",
"      Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/16/7432?source=related_link\">",
"      Treatment of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3321?source=related_link\">",
"      Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_32_34315="Classification arrhythmias";
var content_f33_32_34315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of cardiac arrhythmias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supraventricular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Atrial origin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial fibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial flutter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Atrial tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ectopic focus (enhanced automaticity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Intraatrial or sinoatrial reentry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial extrasystoles (atrial premature beats)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        AV junction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrioventricular nodal reentrant tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrioventricular reentrant tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        AV junctional rhythms (enhanced automaticity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        AV junctional extrasystoles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ventricular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sustained",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nonsustained",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ventricular fibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ventricular extrasystoles (ventricular premature beats)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34315=[""].join("\n");
var outline_f33_32_34315=null;
var title_f33_32_34316="High fiber foods PI";
var content_f33_32_34316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    High-fiber foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Fiber (grams)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Cereal (1/2 cup serving)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Fiber One",
"      </td>",
"      <td>",
"       13",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       100% Bran",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       All Bran",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bran Buds",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Kellogg's Complete Bran Flakes",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Grape Nuts",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Raisin Bran",
"      </td>",
"      <td>",
"       3 to 5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cracklin' Oat Bran",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       100% Whole Grain Wheat Chex",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Fruit and Fiber",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Great Grains",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Frosted Mini Wheats",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Kellogg's Low-Fat Granola",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Fruit",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pear (one)",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Strawberries (1 cup)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Apple (one, with skin)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dried fruits (eg, raisins) (3 tablespoons)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Papaya (one)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Vegetables (cooked unless indicated)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pinto, kidney, black, lima beans (1/2 cup)",
"      </td>",
"      <td>",
"       4 to 7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sweet potato (1 medium)",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lentils (1/2 cup)",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Jicama (1/2 raw)",
"      </td>",
"      <td>",
"       3 to 4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Baked potato with skin (medium)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Corn (1/2 cup)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Peas (1/2 cup)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34316=[""].join("\n");
var outline_f33_32_34316=null;
var title_f33_32_34317="Medications causing sweating";
var content_f33_32_34317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications that may cause sweating or flushing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bupropion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Selective serotonin reuptake inhibitors (SSRIs)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tricyclic antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Norepinephrine reuptake inhibitors (SSNRIs)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Anti-migraine drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            \"Triptans\" serotonin 5-HT (lb/ld) agonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Antipyretics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acetaminophen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aspirin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nonsteroidal anti-inflammatory drugs (NSAIDs)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cholinergic agonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bethanecol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pilocarpine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hormonal agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            GnRH agonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gonadorelin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Goserelin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Histrelin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Leuprolide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nafarelin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Aromatase inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anastrazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Exemestane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Letrozole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Receptor blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Flutamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            SERMs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Raloxifene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tamoxifen",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypoglycemic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Insulin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfonylureas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thiazolidinediones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Sympathomimetic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beta-agonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenylephrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beta blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bromocriptine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Calcium channel blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clozapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclosporine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Donepezil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluvoxamine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydralazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Imatinib",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Infliximab",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Interferon alfa-2b",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Morphine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Niacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nitroglycerin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Omeprazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Opioids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Protease inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rituximab",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ropinirole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sildenafil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tamoxifen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tramadol",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34317=[""].join("\n");
var outline_f33_32_34317=null;
var title_f33_32_34318="Choroid plexus cyst";
var content_f33_32_34318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse image of the fetal head of an early second trimester fetus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 210px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arrow demonstrates a unilateral choroid plexus cyst. The cyst is anechoic and surrounded by the more brightly echogenic choroid plexus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34318=[""].join("\n");
var outline_f33_32_34318=null;
var title_f33_32_34319="Acute hip trauma plain film";
var content_f33_32_34319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute hip trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Frontal radiograph of the left hip in a patient with left hip pain following recent fall shows no distinct fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_32_34319=[""].join("\n");
var outline_f33_32_34319=null;
